<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<database>
    <TRIAL>
        <attritionBiasJudgement>"During the course of the experiment several patients had to be eliminated from both groups for various reasons so that the final chlorpromazine group consisted of 18 patients while the final placebo group consisted of 16 patients". Reasons for leaving the study early not reported.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Abrams1958</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Abrams</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"The experimental group received chlorpromazine under the name of "Thoraxine A", "The control group, received a placebo, the same size, shape and colour as the chlorpromazine. As a differentiation from the chlorpromazine, the placebo was known as "Thorazine B".</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Abrams J</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>20-8</pages>
            <title>Chlorpromazine in the treatment of chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>19</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Abrams J</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>20-8</pages>
            <title>Chlorpromazine in the treatment of chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>19</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Abrams J</references>
        <references>Chlorpromazine in the treatment of chronic schizophrenia</references>
        <references>Diseases of the Nervous System</references>
        <references>1958</references>
        <references>19</references>
        <references></references>
        <references>20-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for MSRPP, Weschler Bellvue Intelligence Scale or Rorschach tests. No useable data for adverse effects.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Abrams-1958</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Divided, at random, into two groups" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1958</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"There were no deaths in this group, but one patient (Case 120) was so uncooperative in taking tablets that it was decided to abandon the attempt, in her case". Three participants are not accounted for in the analysis.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Baker1959</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo>First arm data used</designAddedInfo>
        <designProse>Design: cross-over - first arm data used</designProse>
        <detectionBiasJudgement>"The total number of tablets for each five-week period (378) were put in a separate envelope, labelled "A", "B", or "C" and a code was kept showing which tablets any patient was taking during any given period [...] It was thus possible to keep the handling and the knowledge of the identity of the tablets under the control of a person other than the psychiatric assessor of results until the trial was completed."</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Baker</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement>"These three substances were supplied in matching tablets by Messrs. Smith &amp; Nephew, the sponsors of the new drug".</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Matching tablets" were used.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Baker JP</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>852-62</pages>
            <title>A controlled trial of ethylcrotonylurea</title>
            <type>Journal article</type>
            <volume>105</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Baker JP</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>852-62</pages>
            <title>A controlled trial of ethylcrotonylurea</title>
            <type>Journal article</type>
            <volume>105</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Baker JP</references>
        <references>A controlled trial of ethylcrotonylurea</references>
        <references>British Journal of Psychiatry</references>
        <references>1959</references>
        <references>105</references>
        <references></references>
        <references>852-62</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Unable to use BPRS data.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Baker-1959</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Order determined by random selection" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>CROSSOVER</trialDesign>
        <year>1959</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Ban1975</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Ban</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement> Supported in part by PHS Grant from the National Institute of Mental Health, Rockwell, Maryland., Drugs supplied by Pfizer (Canada) Inc, Montreal, Canada.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "All medication was supplied in capsules identical in appearance, taste and smell".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Ban TA, Lehmann HE, Sterlin C, Climan M</allAuthors>
            <date>1975</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>473-7</pages>
            <title>Comprehensive clinical studies with thiothixene</title>
            <type>Journal article</type>
            <volume>36</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Ban TA, Lehmann HE, Sterlin C, Climan M</allAuthors>
            <date>1975</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>473-7</pages>
            <title>Comprehensive clinical studies with thiothixene</title>
            <type>Journal article</type>
            <volume>36</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Ban TA, Lehmann HE, Sterlin C, Climan M</references>
        <references>Comprehensive clinical studies with thiothixene</references>
        <references>Diseases of the Nervous System</references>
        <references>1975</references>
        <references>36</references>
        <references></references>
        <references>473-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No means and SDs reported for BPRS.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Ban-1975</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomised" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1975</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> No losses to follow-up in the chlorpromazine or placebo groups.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Bishop1963</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Bishop</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement> Study supported by PHS Grant MY-3701 (Psychopharmacology Service Centre - NIMII). Benzquinamide supplied by Charles Pfizer and Company, Inc, New York.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double blind" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Bishop M, Gallant DM</allAuthors>
            <date>1963</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>180-1</pages>
            <title>Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients</title>
            <type>Journal article</type>
            <volume>120</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Bishop M, Gallant DM</allAuthors>
            <date>1963</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>180-1</pages>
            <title>Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients</title>
            <type>Journal article</type>
            <volume>120</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Bishop M, Gallant DM</references>
        <references>Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients</references>
        <references>American Journal of Psychiatry</references>
        <references>1963</references>
        <references>120</references>
        <references></references>
        <references>180-1</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No data reported for the BPRS, Lorr scale or Tulane Research Battery.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Bishop-1963</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Divided at random" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1963</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Early terminators from treatment were analysed using last observation carried forward".</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Borison1991</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>50.5</Control_Mean>
            <Control_SD>6.4</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Intervention_Mean>46.4</Intervention_Mean>
            <Intervention_SD>4.5</Intervention_SD>
            <Outcome>Mental state: 2. Average endpoint scores (BPRS, high score=worse)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </cobj>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <mainAuthor>Borison</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Borison and Diamond in prison for research fraud.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>50.5</Control_Mean>
            <Control_SD>6.4</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Intervention_Mean>46.4</Intervention_Mean>
            <Intervention_SD>4.5</Intervention_SD>
            <Outcome>Mental state: 2. Average endpoint scores (BPRS, high score=worse)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double blind" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Borison RL, Dren AT, Diamond BI</allAuthors>
            <date>1990</date>
            <issue></issue>
            <journalName>European Journal of Pharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>23</pages>
            <title>Sigma receptor antagonism and antipsychotic actions in schizophrenic patients</title>
            <type>Journal article</type>
            <volume>183</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Borison RL, Diamond BI, Dren AT</allAuthors>
            <date>1991</date>
            <issue></issue>
            <journalName>Psychopharmacology Bulletin</journalName>
            <originalTitle></originalTitle>
            <pages>103-6</pages>
            <title>Does sigma receptor antagonism predict clinical antipsychotic efficacy?</title>
            <type>Journal article</type>
            <volume>27</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Borison RL, Dren AT, Diamond BI</allAuthors>
            <date>1990</date>
            <issue></issue>
            <journalName>European Journal of Pharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>23</pages>
            <title>Sigma receptor antagonism and antipsychotic actions in schizophrenic patients</title>
            <type>Journal article</type>
            <volume>183</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Borison RL, Diamond BI, Dren AT</references>
        <references>Does sigma receptor antagonism predict clinical antipsychotic efficacy?</references>
        <references>Psychopharmacology Bulletin</references>
        <references>1991</references>
        <references>27</references>
        <references></references>
        <references>103-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Borison RL, Dren AT, Diamond BI</references>
        <references>Sigma receptor antagonism and antipsychotic actions in schizophrenic patients</references>
        <references>European Journal of Pharmacology</references>
        <references>1990</references>
        <references>183</references>
        <references></references>
        <references>23</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Use of SAS not pre-specified in methods. No data reported for adverse effects.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Borison-1991</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Subjects were assigned on a double-blind, random basis" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1991</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>Patients that did not complete the four week trial "were included in the statistical analyses by using their endpoint scores at time of discontinuation", "Four  chlorpromazine-treated patients  failed to complete the trial: 3 on account of side effects (1 case of leucopenia and 2 of  hypotension) and 1 on account of  inefficacy. Seven placebo-treated patients did not complete the clinical trial (1 case of  abnormal liver  function, 5 of inefficacy, and 1 patient for administrative reasons)." Last observation carried forward method used.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Chouinard1990</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>Canada</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Chouinard</mainAuthor>
        <meerKatCountry>Canada</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>short term - (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>20</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>acute - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>acute - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>1990 to 2002 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>1990 to 2002 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double blind", "The trial drugs were provided in the form of identical white opaque gelatin capsules".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Chouinard G</allAuthors>
            <date>1990</date>
            <issue></issue>
            <journalName>Acta Psychiatria Scandinavica Supplementum</journalName>
            <originalTitle></originalTitle>
            <pages>111-9</pages>
            <title>A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation</title>
            <type>Journal article</type>
            <volume>358</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Chouinard G</allAuthors>
            <date>1990</date>
            <issue></issue>
            <journalName>Acta Psychiatria Scandinavica Supplementum</journalName>
            <originalTitle></originalTitle>
            <pages>111-9</pages>
            <title>A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation</title>
            <type>Journal article</type>
            <volume>358</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Chouinard G</references>
        <references>A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation</references>
        <references>Acta Psychiatria Scandinavica Supplementum</references>
        <references>1990</references>
        <references>358</references>
        <references></references>
        <references>111-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for BPRS and CGI. No useable data reported for adverse effects.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Chouinard-1990</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>INPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1990</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> One participant in the chlorpromazine group was withdrawn due to agranulocytosis, along with the other two participants in her "triplet".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Clark1961</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind", ""neither the patients nor the personnel involved in the care or evaluation of the subjects were informed of any individual's medication until the end of the study".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>19</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported, in part, by USPHS Grant M-1600 from the National Institute of Mental Health, National Institutes of Health, Department of Health, Education, and Welfare., Medications supplied by Dr Fred Alexander of Smith, Kline, and French Laboratories.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>19</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>19</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>19</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>19</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>19</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "neither the patients nor the personnel involved in the care or evaluation of the subjects were informed of any individual's medication until the end of the study. Medications were dispensed in individually labeled bottles so that identification by code was not possible".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Ray TS, Ragland RE, Clark ML</allAuthors>
            <date>1964</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Diseases</journalName>
            <originalTitle></originalTitle>
            <pages>348-53</pages>
            <title>Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment</title>
            <type>Journal article</type>
            <volume>138</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ray T, Paredes A, Costiloe J, Chappell J, Hagans J, et al</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle></originalTitle>
            <pages>107-36</pages>
            <title>Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment</title>
            <type>Journal article</type>
            <volume>2</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ray TS, Ragland RE</allAuthors>
            <date>1963</date>
            <issue></issue>
            <journalName>Psychosomatic Medicine</journalName>
            <originalTitle></originalTitle>
            <pages>212-7</pages>
            <title>Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects</title>
            <type>Journal article</type>
            <volume>25</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Ray TS, Ragland RE, Clark ML</allAuthors>
            <date>1964</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Diseases</journalName>
            <originalTitle></originalTitle>
            <pages>348-53</pages>
            <title>Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment</title>
            <type>Journal article</type>
            <volume>138</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Clark ML, Ray T, Paredes A, Costiloe J, Chappell J, Hagans J, et al</references>
        <references>Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment</references>
        <references>Psychopharmacologia</references>
        <references>1961</references>
        <references>2</references>
        <references></references>
        <references>107-36</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark ML, Ray TS, Ragland RE</references>
        <references>Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects</references>
        <references>Psychosomatic Medicine</references>
        <references>1963</references>
        <references>25</references>
        <references></references>
        <references>212-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Ray TS, Ragland RE, Clark ML</references>
        <references>Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment</references>
        <references>Journal of Nervous and Mental Diseases</references>
        <references>1964</references>
        <references>138</references>
        <references></references>
        <references>348-53</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No data reported for OBRS, and no useable data reported for psychological tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1961</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Participants "individually matched into triplets. Random assignment of triplet members to treatment groups", "drawn by a table of random numbers".</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1961</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Seventy subjects meeting all physical and selection criteria completed both cycles of study 1 year apart. During the course of the second cycle, 2 subjects were found to be abnormal in regard to cholesterol metabolism [...] and their data were deleted from this report"., "11 subjects taking chlorpromazine were unable to tolerate the full 800 mg over the 10-week trial".</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Clark1967</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind procedure in which neither the investigators nor the subjects knew who was receiving chlorpromazine".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement>Chlorpromazine and placebo were supplied by Smith Kline &amp; French Laboratories, Philadelphia, Pa., Supported by Grant MH-04260 from the US Public Health Service.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind procedure in which neither the investigators nor the subjects knew who was receiving chlorpromazine. Medications were dispensed in identical-appearing capsules from individual stock bottle labeled only with the patient's name."</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, et al</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>Psychosomatic Medicine</journalName>
            <originalTitle></originalTitle>
            <pages>634-42</pages>
            <title>Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships</title>
            <type>Journal article</type>
            <volume>29</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark M, Dubowski K, Colmore J</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Clinical Pharmacology and Therapeutics</journalName>
            <originalTitle></originalTitle>
            <pages>883-9</pages>
            <title>The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>11</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, et al</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>Psychosomatic Medicine</journalName>
            <originalTitle></originalTitle>
            <pages>634-42</pages>
            <title>Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships</title>
            <type>Journal article</type>
            <volume>29</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark M, Dubowski K, Colmore J</references>
        <references>The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients</references>
        <references>Clinical Pharmacology and Therapeutics</references>
        <references>1970</references>
        <references>11</references>
        <references></references>
        <references>883-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, et al</references>
        <references>Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships</references>
        <references>Psychosomatic Medicine</references>
        <references>1967</references>
        <references>29</references>
        <references></references>
        <references>634-42</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No data reported for BPRS, PRS, OBRS, Perdue Pegboard test, Digit Symbol Test and physiological measures.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1967</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Assigned at random" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>INPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1967</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Sixty six patients completed the study. Two patients were dropped from the CPZ group because of skin rashes and a third because of a severe behavioural reaction", "Three were dropped form the no drug group [...] one patient in TRP group completed only 13 weeks before undergoing surgery".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Clark1968a</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by grants from the National Institute of Mental Health, US Public Health Service and McNeil Laboratories Inc, Fort Washington, Pennsylvania.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight increase</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight decrease</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>36</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Identically appearing capsules from each subject's individually labelled stock bottle to meet the double-blind requirements of the study".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle></originalTitle>
            <pages>193-203</pages>
            <title>Evaluation of trifluperidol in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>12</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle></originalTitle>
            <pages>193-203</pages>
            <title>Evaluation of trifluperidol in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>12</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR</references>
        <references>Evaluation of trifluperidol in chronic schizophrenia</references>
        <references>Psychopharmacologia</references>
        <references>1968</references>
        <references>12</references>
        <references></references>
        <references>193-203</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for Oklahoma Rating Scale and psychological tests. No data reported for physiological tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1968a</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1968</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Sixty seven patients completed the study. One patient was dropped from the CPZ group because of agranulocytosis; one was lost form the BPZ group when she eloped."</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Clark1968b</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>12</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>menorrhagia / abnormal menstruation</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by grants from US Public Heath Service and AH Robins Company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>23</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>12</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>menorrhagia / abnormal menstruation</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double-blind", "All medications were identical in appearance".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Clinical Pharmacology and Therapeutics</journalName>
            <originalTitle></originalTitle>
            <pages>57-64</pages>
            <title>Evaluation of butaperazine in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>97</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Clinical Pharmacology and Therapeutics</journalName>
            <originalTitle></originalTitle>
            <pages>57-64</pages>
            <title>Evaluation of butaperazine in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>97</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR</references>
        <references>Evaluation of butaperazine in chronic schizophrenia</references>
        <references>Clinical Pharmacology and Therapeutics</references>
        <references>1968</references>
        <references>97</references>
        <references></references>
        <references>57-64</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No useable data was reported for global improvement, OBRS, IMPS, Perdue Pegboard, Digit Symbol test and physiological tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1968b</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1968</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"One subject was dropped form the CPZ group because of abnormal liver function tests; another subject on CPZ was terminated 2 weeks early because of surgery".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Clark1970a</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported in part by US Public Health Service Grant, Research Scientist Development Award from National Institute of Mental Health. Endo Laboratories provided the medication and partial support.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Global state: 1b. No overall improvement (nurse-rated)</Outcome>
            <Subgroup>medium term (9 weeks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>liver problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>eye opacity / eye pigment problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight increase</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight decrease</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>menorrhagia / abnormal menstruation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>lactation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 3. Severity of illness (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Identically appearing capsules", "double-blind, with medications dispensed from individual stock bottles labelled only with the patient's name".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1971</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>77-82</pages>
            <title>The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine</title>
            <type>Journal article</type>
            <volume>6</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark M, Dubowski K, Colmore J</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Clinical Pharmacology and Therapeutics</journalName>
            <originalTitle></originalTitle>
            <pages>883-9</pages>
            <title>The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>11</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Clinical Pharmacology and Therapeutics</journalName>
            <originalTitle></originalTitle>
            <pages>680-8</pages>
            <title>Molindone in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>11</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1971</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>77-82</pages>
            <title>The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine</title>
            <type>Journal article</type>
            <volume>6</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Clark M, Dubowski K, Colmore J</references>
        <references>The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients</references>
        <references>Clinical Pharmacology and Therapeutics</references>
        <references>1970</references>
        <references>11</references>
        <references></references>
        <references>883-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA</references>
        <references>Molindone in chronic schizophrenia</references>
        <references>Clinical Pharmacology and Therapeutics</references>
        <references>1970</references>
        <references>11</references>
        <references></references>
        <references>680-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Willis D, Clark ML</references>
        <references>The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine</references>
        <references>International Pharmacopsychiatry</references>
        <references>1971</references>
        <references>6</references>
        <references></references>
        <references>77-82</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for BPRS, NOSIE and the various psychological tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1970a</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned by sex" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1970</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"During the course of the study one subject was dropped because of rash and anaemia, one because of agranulocytosis, two because of elopement from the hospital, and two because of requisite surgery". Study does not report which from groups the losses to follow-ups occurred.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Clark1970b</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by USPHS grant and Research Scientist Development Award.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>15</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un-cooperative</Outcome>
            <Subgroup>only women</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement> No information reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1972</date>
            <issue></issue>
            <journalName>Biological Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>251-6</pages>
            <title>EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking</title>
            <type>Journal article</type>
            <volume>4</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark M, Dubowski K, Colmore J</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Clinical Pharmacology and Therapeutics</journalName>
            <originalTitle></originalTitle>
            <pages>883-9</pages>
            <title>The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>11</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark M, Ramsey H, Rahhal D, Serafetinides E, Wood F, Costiloe J</allAuthors>
            <date>1972</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>479-83</pages>
            <title>Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships</title>
            <type>Journal article</type>
            <volume>27</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle></originalTitle>
            <pages>260-70</pages>
            <title>Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships</title>
            <type>Journal article</type>
            <volume>18</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1972</date>
            <issue></issue>
            <journalName>Biological Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>251-6</pages>
            <title>EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking</title>
            <type>Journal article</type>
            <volume>4</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark M, Dubowski K, Colmore J</references>
        <references>The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients</references>
        <references>Clinical Pharmacology and Therapeutics</references>
        <references>1970</references>
        <references>11</references>
        <references></references>
        <references>883-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark M, Ramsey H, Rahhal D, Serafetinides E, Wood F, Costiloe J</references>
        <references>Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships</references>
        <references>Archives of General Psychiatry</references>
        <references>1972</references>
        <references>27</references>
        <references></references>
        <references>479-83</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP</references>
        <references>Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships</references>
        <references>Psychopharmacologia</references>
        <references>1970</references>
        <references>18</references>
        <references></references>
        <references>260-70</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Willis D, Clark ML</references>
        <references>EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking</references>
        <references>Biological Psychiatry</references>
        <references>1972</references>
        <references>4</references>
        <references></references>
        <references>251-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for CGI, BPRS, IMPS, and OBRS.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1970b</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Subjects were assigned by block randomisation" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1970</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Of the 75 subjects completing the study, one placebo subject was terminated because of behavioural deterioration after only three weeks observation and one subject taking fluphenazine was discharged from the hospital as markedly improved after only two weeks observation. In both instances, final measures were obtained and their data were retained for the final analysis. Eleven additional subjects were started in the study but were dropped without obtaining final measures for a variety of reasons: in the placebo group there was one subject absent without permission (AWOL), one on convalescent leave, and one subject transferred to another hospital; in the thioridazine group there were two AWOL subjects and one with medication intolerance; in the chlorpromazine group there was one AWOL and two subjects who refused oral medication; in the fluphenazine group there was one administrative transfer and one AWOL."</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Clark1971</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement>Supported by Public Health Service grant and Research Scientist Award. Medication provided by Smith Kline &amp; French Laboratories, Sandoz Inc and ER SQuibb &amp; Sons.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>17</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>photosensitivity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>urinary problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "identical appearing medication was administered from a bottle labelled only with the patient's name".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark</allAuthors>
            <date>1969</date>
            <issue>3</issue>
            <journalName>Psychopharmacology Bulletin</journalName>
            <originalTitle></originalTitle>
            <pages>37-40</pages>
            <title>Phenothiazines in schizophrenics</title>
            <type>Journal article</type>
            <volume>6</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP</allAuthors>
            <date>1971</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>404-9</pages>
            <title>Drug treatment in newly admitted schizophrenic patients</title>
            <type>Journal article</type>
            <volume>25</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark</allAuthors>
            <date>1969</date>
            <issue>3</issue>
            <journalName>Psychopharmacology Bulletin</journalName>
            <originalTitle></originalTitle>
            <pages>37-40</pages>
            <title>Phenothiazines in schizophrenics</title>
            <type>Journal article</type>
            <volume>6</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP</references>
        <references>Drug treatment in newly admitted schizophrenic patients</references>
        <references>Archives of General Psychiatry</references>
        <references>1971</references>
        <references>25</references>
        <references></references>
        <references>404-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark</references>
        <references>Phenothiazines in schizophrenics</references>
        <references>Psychopharmacology Bulletin</references>
        <references>1969</references>
        <references>6</references>
        <references>3</references>
        <references>37-40</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for BPRS, NOSIE and the psychological tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1971</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Patients were assigned to treatment randomly in blocks of four" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1971</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Five patients were lost from the study: 2 from the PL group because of a grand mal seizure in one, and a cardiac arrhythmia in the second; 2 from the CPZ group because of abnormal liver function in one and a severe allergic reaction dermatitis with photo-sensitivity on the other; 1 from the LOX group because of a hip fracture".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Clark1972</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by a grant from USPHS and a grant-in-aid from Lederle Laboratories.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Global state: 1b. No overall improvement (nurse-rated)</Outcome>
            <Subgroup>medium term (9 weeks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>fits / loss of consciousness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>photosensitivity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight increase</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight decrease</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 3. Severity of illness (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>19</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", identical appearing medication in capsule form was administered orally to each subject rom his individual stock bottle labelled only with his name".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1971</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>38-44</pages>
            <title>The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects</title>
            <type>Journal article</type>
            <volume>6</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP</allAuthors>
            <date>1972</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>783-91</pages>
            <title>Evaluation of loxapine succinate in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>33</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1971</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>38-44</pages>
            <title>The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects</title>
            <type>Journal article</type>
            <volume>6</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP</references>
        <references>Evaluation of loxapine succinate in chronic schizophrenia</references>
        <references>Diseases of the Nervous System</references>
        <references>1972</references>
        <references>33</references>
        <references></references>
        <references>783-91</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Willis D, Clark ML</references>
        <references>The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects</references>
        <references>International Pharmacopsychiatry</references>
        <references>1971</references>
        <references>6</references>
        <references></references>
        <references>38-44</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for BPRS, NOSIE and weight gain. No data reported for physical tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1972</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Allocation to treatment was random, but provided for balancing of groups by sex and age" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1972</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Of the 27 subjects who started, three failed to complete the full 12 weeks of study: one female subject in the butaclamol group became excited and agitated during the 4th week of treatment, exacerbated a labile hypertension, and was dropped at the end of the 4th week as treatment failure. Two male subjects in the placebo group also manifested clinical deterioration, one at the 8th week and one at the 11th week of treatment, and were terminated as treatment failures. In each instance, final rating were obtained and their data were retained in the analysis". Last observation carried forward method used.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Clark1977</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Clark</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement>Supported in part by a USPHS grant and a grant-in-aid from Ayerst Laboratories, NY.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Global state: 1b. No overall improvement (nurse-rated)</Outcome>
            <Subgroup>medium term (9 weeks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>acute movement disorders (dystonia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>chronic movement disorders (tardive dyskinesia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>photosensitivity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight increase</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight decrease</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Placebo tablets identical to the white butaclamol and to the brown CPZ preparations were taken by all subjects during the dryout period and by the placebo group during treatment"., "Each patient received his/her medication from individual stock bottles"., "Double-blind".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Paredes A, Costiloe JP, Wood F</allAuthors>
            <date>1977</date>
            <issue></issue>
            <journalName>Journal of Clinical Pharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>529-36</pages>
            <title>Evaluation of butaclamol in chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>17</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Clark ML, Paredes A, Costiloe JP, Wood F</allAuthors>
            <date>1977</date>
            <issue></issue>
            <journalName>Journal of Clinical Pharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>529-36</pages>
            <title>Evaluation of butaclamol in chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>17</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Clark ML, Paredes A, Costiloe JP, Wood F</references>
        <references>Evaluation of butaclamol in chronic schizophrenic patients</references>
        <references>Journal of Clinical Pharmacology</references>
        <references>1977</references>
        <references>17</references>
        <references></references>
        <references>529-36</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for BPRS, CGI and NOSIE, and no data reported for physical tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Clark-1977</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Allocation to treatment by sex was random" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1977</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> No losses to follow-up reported.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Cohen1968</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>42</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>42</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Cohen</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by grants from the National Institute of Mental Health, Public Health Service.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>42</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>42</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Graupner OK, Kalman EV</allAuthors>
            <date>1972</date>
            <issue>4</issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle>Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)</originalTitle>
            <pages>343-7</pages>
            <title>Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments</title>
            <type>Journal article</type>
            <volume>27</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Cohen M, Freedman N, Englehardt DM</allAuthors>
            <date>1968</date>
            <issue>1</issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>50-6</pages>
            <title>Family interaction patterns, drug treatment, and change in social aggression</title>
            <type>Journal article</type>
            <volume>19</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Graupner OK, Kalman EV</allAuthors>
            <date>1972</date>
            <issue>4</issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle>Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)</originalTitle>
            <pages>343-7</pages>
            <title>Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments</title>
            <type>Journal article</type>
            <volume>27</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Cohen M, Freedman N, Englehardt DM</references>
        <references>Family interaction patterns, drug treatment, and change in social aggression</references>
        <references>Archives of General Psychiatry</references>
        <references>1968</references>
        <references>19</references>
        <references>1</references>
        <references>50-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Graupner OK, Kalman EV</references>
        <references>Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments</references>
        <references>Psychopharmacologia</references>
        <references>1972</references>
        <references>27</references>
        <references>4</references>
        <references>343-7</references>
        <references>Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for social aggression and manifest anxiety state.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Cohen-1968</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>OUTPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1968</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> 119 out of 463 participants were lost to follow-up. Reasons for loss to follow-up were balanced across groups, apart from treatment failure where "the majority of patients who were dropped because of treatment failure were on placebo".</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Cole1964</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>lactation</Subgroup>
        </dobj>
        <mainAuthor>Cole</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by NIMH grants.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>112</Intervention_Total>
            <Control_Events>37</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>125</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>acute movement disorders (dystonia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>22</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>47</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>21</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>29</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>urinary problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>22</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>25</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>nausea/vomiting</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>salivation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>73</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>amenorrhea</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>88</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>lactation</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind" oral medication "prepared as standard No. 2 pink capsules", IM from "1 cc glass ampules" with sterile saline for placebo.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Goldberg SC, Mattsson NB</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>153-8</pages>
            <title>Schizophrenic subtypes defined by response to drugs and placebo</title>
            <type>Journal article</type>
            <volume>29</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group</allAuthors>
            <date>1964</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>246-61</pages>
            <title>Phenothiazine treatment in acute schizophrenia</title>
            <type>Journal article</type>
            <volume>10</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Goldberg S, Klerman G, Cole J</allAuthors>
            <date>1965</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>120-33</pages>
            <title>Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment</title>
            <type>Journal article</type>
            <volume>111</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Goldberg SC, Mattsson NB</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>153-8</pages>
            <title>Schizophrenic subtypes defined by response to drugs and placebo</title>
            <type>Journal article</type>
            <volume>29</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group</references>
        <references>Phenothiazine treatment in acute schizophrenia</references>
        <references>Archives of General Psychiatry</references>
        <references>1964</references>
        <references>10</references>
        <references></references>
        <references>246-61</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Goldberg S, Klerman G, Cole J</references>
        <references>Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment</references>
        <references>British Journal of Psychiatry</references>
        <references>1965</references>
        <references>111</references>
        <references></references>
        <references>120-33</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Goldberg SC, Mattsson NB</references>
        <references>Schizophrenic subtypes defined by response to drugs and placebo</references>
        <references>Diseases of the Nervous System</references>
        <references>1968</references>
        <references>29</references>
        <references></references>
        <references>153-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Data was not reported by group for Global Rating of Severity of Mental Illness &amp; Global Rating of Improvements, IMPS and Burdock Ward Behaviour Rating Scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Cole-1964</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Stratified by sex with randomised assignment to drug treatment within each sex group" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1964</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"ITT analysis", "A total of 89 patients completed the full 8-week study." "Sixty-nine patients withdrew from the study" Reasons for leaving the study not fully described.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Cooper2000</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>Belgium, Ireland, Poland, UK</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Cooper</mainAuthor>
        <meerKatCountry>Multi-Center//Belgium//Ireland//Poland//UK</meerKatCountry>
        <otherBiasJudgement> Funded by Knoll Pharmaceuticals. Data analysis was by Knoll in conjunction with Dr Cooper.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>25</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>25</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>1990 to 2002 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>53</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "A double-dummy technique was used to maintain blinding because of differences in capsule and tablet appearances, i.e. patients received active zotepine plus placebo chlorpromazine or placebo zotepine plus active chlorpromazine or double placebo."</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="conferenceReferenceObject">
            <allAuthors>Cooper SJ, Welch CP</allAuthors>
            <city>Vienna, Austria</city>
            <conferenceName>10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria</conferenceName>
            <date>September 13-17, 1997</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages></pages>
            <publisher></publisher>
            <title>A comparison of zotepine and chlorpromazine on BPRS subscores</title>
            <type>Conference proceedings</type>
            <volume></volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="conferenceReferenceObject">
            <allAuthors>Cooper SJ, Butler A, Tweed J, Welch CP</allAuthors>
            <city>Vienna, Austria</city>
            <conferenceName>10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria</conferenceName>
            <date>September 13-17, 1997</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages></pages>
            <publisher></publisher>
            <title>Zotepine in the treatment of chronic schizophrenia</title>
            <type>Conference proceedings</type>
            <volume></volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="conferenceReferenceObject">
            <allAuthors>Cooper SJ, Raniwalla J, Welch C</allAuthors>
            <city>Melbourne, Australia</city>
            <conferenceName>XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia</conferenceName>
            <date>1996</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages></pages>
            <publisher></publisher>
            <title>Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo</title>
            <type>Conference proceedings</type>
            <volume></volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C</allAuthors>
            <date>2000</date>
            <issue>3</issue>
            <journalName>Acta Psychiatrica Scandinavica</journalName>
            <originalTitle></originalTitle>
            <pages>218-25</pages>
            <title>A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia</title>
            <type>Journal article</type>
            <volume>101</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="unpublishedReferenceObject">
            <allAuthors>Cooper SJ, Tweed J, Raniwalla J, Welch C</allAuthors>
            <date>1996</date>
            <originalTitle></originalTitle>
            <source>Unpublished manuscript</source>
            <title>A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia</title>
            <type>Unpublished reference</type>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="conferenceReferenceObject">
            <allAuthors>Cooper SJ, Welch CP</allAuthors>
            <city>Vienna, Austria</city>
            <conferenceName>10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria</conferenceName>
            <date>September 13-17, 1997</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages></pages>
            <publisher></publisher>
            <title>A comparison of zotepine and chlorpromazine on BPRS subscores</title>
            <type>Conference proceedings</type>
            <volume></volume>
        </referenceList>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Cooper SJ, Butler A, Tweed J, Welch CP</references>
        <references>Zotepine in the treatment of chronic schizophrenia</references>
        <references>10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria</references>
        <references>September 13-17, 1997</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>Vienna, Austria</references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Cooper SJ, Raniwalla J, Welch C</references>
        <references>Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo</references>
        <references>XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia</references>
        <references>1996</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>Melbourne, Australia</references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C</references>
        <references>A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia</references>
        <references>Acta Psychiatrica Scandinavica</references>
        <references>2000</references>
        <references>101</references>
        <references>3</references>
        <references>218-25</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>UNPUBLISHED</references>
        <references>NO</references>
        <references>Cooper SJ, Tweed J, Raniwalla J, Welch C</references>
        <references>A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia</references>
        <references>Unpublished manuscript</references>
        <references>1996</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Cooper SJ, Welch CP</references>
        <references>A comparison of zotepine and chlorpromazine on BPRS subscores</references>
        <references>10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria</references>
        <references>September 13-17, 1997</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>Vienna, Austria</references>
        <references></references>
        <reportingBiasJudgement>For adverse effects it is unclear if data includes withdrawals. We are unsure of the data reported for BPRS, SANS, CGI, AIMS, COSTART and EPMS. No means and SDs were reported for Simpson and Angus.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Cooper-2000</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"All eligible patients were allocated a study number and randomly assigned in blocks of six" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>INANDOUT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2000</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Dean1958</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>liver problems</Subgroup>
        </dobj>
        <mainAuthor>Dean</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Chlorpromazine supplied by Smith Kline &amp; French Laboratories., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>9</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>9</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>liver problems</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Those patients on placebo were given tablets which were identical in appearance with chlorpromazine.", "Until the patients were receiving 1000 mg of chlorpromazine a day, the hospital pharmacist was was the only person who knew which patients were receiving placebos. At the 1000 mg level the ward physician checked the master list to determine who was on the placebos".</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Dean EF, Buker S</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Rocky Mountain Medical Journal</journalName>
            <originalTitle></originalTitle>
            <pages>47-50</pages>
            <title>Schizophrenia treated with and without chlorpromazine</title>
            <type>Journal article</type>
            <volume>55</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Dean EF, Buker S</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Rocky Mountain Medical Journal</journalName>
            <originalTitle></originalTitle>
            <pages>47-50</pages>
            <title>Schizophrenia treated with and without chlorpromazine</title>
            <type>Journal article</type>
            <volume>55</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Dean EF, Buker S</references>
        <references>Schizophrenia treated with and without chlorpromazine</references>
        <references>Rocky Mountain Medical Journal</references>
        <references>1958</references>
        <references>55</references>
        <references></references>
        <references>47-50</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>All expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Dean-1958</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement> No information reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1958</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"The overall drop-out rate was 36.4% (63 out of 173 patients), while for individual agents the rates were as follows: placebo, 33.9%; and chlorpromazine, 40.3%". Reasons for loss to follow-up not reported.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Engelhardt1960</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>25</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>62</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>56</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>long term (&gt;6 months - 2 years)</Subgroup>
        </dobj>
        <mainAuthor>Engelhardt</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Study supported in part by a grant from National Institute of Mental Health, US Public Health Service.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>28</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>62</Intervention_Total>
            <Control_Events>35</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>56</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>long term (6 months - 2 years)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>25</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>62</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>56</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>long term (&gt;6 months - 2 years)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "The medication was in the form of pink capsules containing either placebo, promazine hydrochloride or chlorpromazine hydrochloride"., "The treating psychiatrist did not know which agent the patient received".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Rosen B, Engelhardt DM, Freedman N</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>476-80</pages>
            <title>The hospitalization proneness scale as a predictor of response to phenothiazine treatment</title>
            <type>Journal article</type>
            <volume>6</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Engelhardt D, Freedman N, Rosen B, Mann D, Margolis R</allAuthors>
            <date>1964</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>162-9</pages>
            <title>Phenothiazines in prevention of psychiatric hospitalization</title>
            <type>Journal article</type>
            <volume>11</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>JAMA</journalName>
            <originalTitle></originalTitle>
            <pages>147-9</pages>
            <title>Prevention of psychiatric hospitalization with use of psychopharmacological agents</title>
            <type>Journal article</type>
            <volume>173</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Engelhardt DM, Margolis RA, Rudorfer L, Paley HM</allAuthors>
            <date>1969</date>
            <issue>3</issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>315-20</pages>
            <title>Physician bias and the double-blind</title>
            <type>Journal article</type>
            <volume>20</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Engelhardt DM, Rosen B, Freedman N, Mann D, Margolis R</allAuthors>
            <date>1963</date>
            <issue></issue>
            <journalName>JAMA</journalName>
            <originalTitle></originalTitle>
            <pages>981-3</pages>
            <title>Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure</title>
            <type>Journal article</type>
            <volume>186</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Engelhardt DM, Rosen B, Freedman N, Margolis R</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>98-101</pages>
            <title>Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation</title>
            <type>Journal article</type>
            <volume>16</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Freedman N, Cutler R, Engelhardt DM, Margolis R</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>68-76</pages>
            <title>On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines</title>
            <type>Journal article</type>
            <volume>150</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Freedman N, Cutler R, Engelhardt DM, Margolis R</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>29-36</pages>
            <title>On the modification of paranoid symptomatology</title>
            <type>Journal article</type>
            <volume>144</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Rosen B, Engelhardt DM, Freedman N</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>476-80</pages>
            <title>The hospitalization proneness scale as a predictor of response to phenothiazine treatment</title>
            <type>Journal article</type>
            <volume>6</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Engelhardt D, Freedman N, Rosen B, Mann D, Margolis R</references>
        <references>Phenothiazines in prevention of psychiatric hospitalization</references>
        <references>Archives of General Psychiatry</references>
        <references>1964</references>
        <references>11</references>
        <references></references>
        <references>162-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R</references>
        <references>Prevention of psychiatric hospitalization with use of psychopharmacological agents</references>
        <references>JAMA</references>
        <references>1960</references>
        <references>173</references>
        <references></references>
        <references>147-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Engelhardt DM, Margolis RA, Rudorfer L, Paley HM</references>
        <references>Physician bias and the double-blind</references>
        <references>Archives of General Psychiatry</references>
        <references>1969</references>
        <references>20</references>
        <references>3</references>
        <references>315-20</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Engelhardt DM, Rosen B, Freedman N, Mann D, Margolis R</references>
        <references>Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure</references>
        <references>JAMA</references>
        <references>1963</references>
        <references>186</references>
        <references></references>
        <references>981-3</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Engelhardt DM, Rosen B, Freedman N, Margolis R</references>
        <references>Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation</references>
        <references>Archives of General Psychiatry</references>
        <references>1967</references>
        <references>16</references>
        <references></references>
        <references>98-101</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Freedman N, Cutler R, Engelhardt DM, Margolis R</references>
        <references>On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1970</references>
        <references>150</references>
        <references></references>
        <references>68-76</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Freedman N, Cutler R, Engelhardt DM, Margolis R</references>
        <references>On the modification of paranoid symptomatology</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1967</references>
        <references>144</references>
        <references></references>
        <references>29-36</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Rosen B, Engelhardt DM, Freedman N</references>
        <references>The hospitalization proneness scale as a predictor of response to phenothiazine treatment</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1968</references>
        <references>6</references>
        <references></references>
        <references>476-80</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No outcomes pre-specified in methods., Other reports have greater 'N' (of which the 173 above are assumed to be an unbiased sub-sample) but no data is usable from these papers.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Engelhardt-1960</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Drug assignment was random" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>OUTPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1960</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Of the 173 patients starting medication, 19 did not complete the study because of psychiatric reasons [...] 5 for medical complications [...] 5 patients received an active placebo in a methodological substudy and are not included in this analysis.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Fink1963</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Fink</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Partly funded by National Institute of Mental Health, USPHS.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>12</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>51</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>44</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "Each medication was dissolved in a highly flavoured liquid vehicle and each patient received 40ml per day from individually labelled bottles".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Levenstein S, Klein DF, Pollack M</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1102-8</pages>
            <title>Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years</title>
            <type>Journal article</type>
            <volume>122</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Belmont I, Pollack M, Willner A, Klein D, Fink M</allAuthors>
            <date>1963</date>
            <issue>1</issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>42-50</pages>
            <title>The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses</title>
            <type>Journal article</type>
            <volume>137</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, et al</allAuthors>
            <date>1963</date>
            <issue></issue>
            <journalName>Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>370-2</pages>
            <title>Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns</title>
            <type>Journal article</type>
            <volume>3</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Klein DF, Honigfeld G, Feldman S</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>159-87</pages>
            <title>Prediction of drug effect by diagnostic decision tree</title>
            <type>Journal article</type>
            <volume>29</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Klein DF</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>118-26</pages>
            <title>Importance of psychiatric diagnosis in prediction of clinical drug effects</title>
            <type>Journal article</type>
            <volume>16</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Klein DF</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Psychopharmacologia</journalName>
            <originalTitle></originalTitle>
            <pages>359-86</pages>
            <title>Psychiatric diagnosis and a typology of clinical drug effects</title>
            <type>Journal article</type>
            <volume>13</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Levenstein S, Klein DF, Pollack M</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1102-8</pages>
            <title>Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years</title>
            <type>Journal article</type>
            <volume>122</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Belmont I, Pollack M, Willner A, Klein D, Fink M</references>
        <references>The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1963</references>
        <references>137</references>
        <references>1</references>
        <references>42-50</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, et al</references>
        <references>Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns</references>
        <references>Neuropsychopharmacology</references>
        <references>1963</references>
        <references>3</references>
        <references></references>
        <references>370-2</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Klein DF, Honigfeld G, Feldman S</references>
        <references>Prediction of drug effect by diagnostic decision tree</references>
        <references>Diseases of the Nervous System</references>
        <references>1968</references>
        <references>29</references>
        <references></references>
        <references>159-87</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Klein DF</references>
        <references>Importance of psychiatric diagnosis in prediction of clinical drug effects</references>
        <references>Archives of General Psychiatry</references>
        <references>1967</references>
        <references>16</references>
        <references></references>
        <references>118-26</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Klein DF</references>
        <references>Psychiatric diagnosis and a typology of clinical drug effects</references>
        <references>Psychopharmacologia</references>
        <references>1968</references>
        <references>13</references>
        <references></references>
        <references>359-86</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Levenstein S, Klein DF, Pollack M</references>
        <references>Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years</references>
        <references>American Journal of Psychiatry</references>
        <references>1966</references>
        <references>122</references>
        <references></references>
        <references>1102-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No useable data reported for the MSRPP and no SDs reported for Rorschach tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Fink-1963</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1963</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"12 patients who failed to complete the trial was as follows: 6 patient received ECT; 2 patients developed severe extrapyramidal symptoms (chlorpromazine); 1 patient developed agranulocytosis  (chlorpromazine); and 3 patients were withdrawn for miscellaneous physical considerations (promazine)"., "The loss of patients was equally distributed".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Fleming1959</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>Ireland</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </dobj>
        <mainAuthor>Fleming</mainAuthor>
        <meerKatCountry>Ireland</meerKatCountry>
        <otherBiasJudgement> John Wyeth &amp; Bro. supplied the promazine, Messrs, May &amp; Baker Ltd supplied chlorpromazine and placebo tablets.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un-cooperative</Outcome>
            <Subgroup>only women</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Behaviour 1. Deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>21</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>21</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "the tablets of the 3 treatments were identical in appearance, the hospital dispenser alone knowing to which treatment any particular patient had been assigned at the outset".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Fleming B, Spencer A, Whitelaw E</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>349-58</pages>
            <title>A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis</title>
            <type>Journal article</type>
            <volume>105</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Fleming B, Spencer A, Whitelaw E</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>349-58</pages>
            <title>A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis</title>
            <type>Journal article</type>
            <volume>105</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Fleming B, Spencer A, Whitelaw E</references>
        <references>A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis</references>
        <references>British Journal of Psychiatry</references>
        <references>1959</references>
        <references>105</references>
        <references></references>
        <references>349-58</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SD reported for Powick Psychiatric Rating Scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Fleming-1959</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Patients were sub-divided, upon a random basis, into 3 equal groups" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1959</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"if any patient had to discontinue the program, her "pair" could also be omitted", "Three pairs were lost: one due to death from unassociated causes; two due to major side-effects". Both members of a pair removed from analysis when one left.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Grygier1958</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"At the end of the experiment both raters were asked to "guess" the composition of the chlorpromazine group" no further details reported, implies assessors were blind for treatment allocation.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Grygier</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement> No information reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Grygier P, Waters MA</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Archives of Neurology and Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>697-705</pages>
            <title>Chlorpromazine used with an intensive occupational therapy program. A.M.A</title>
            <type>Journal article</type>
            <volume>79</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Grygier P, Waters MA</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Archives of Neurology and Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>697-705</pages>
            <title>Chlorpromazine used with an intensive occupational therapy program. A.M.A</title>
            <type>Journal article</type>
            <volume>79</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Grygier P, Waters MA</references>
        <references>Chlorpromazine used with an intensive occupational therapy program. A.M.A</references>
        <references>Archives of Neurology and Psychiatry</references>
        <references>1958</references>
        <references>79</references>
        <references></references>
        <references>697-705</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for Albany Behavioral Rating Scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Grygier-1958</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"The pharmacist decided at random which group would receive chlorpromazine and which inert tablets, and only she had this information at any time".</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"selected two groups, matching them as closely as possible", "pharmacist decided at random" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1958</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> In the placebo group, one participant left the study early due to adverse effects and two due to unmanageability. There were no losses to follow-up in the chlorpromazine group.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Gwynne1962</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </dobj>
        <mainAuthor>Gwynne</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>Drugs provided by Smith, Kline and French, and Merck, Sharp &amp; Dohme., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>convulsions</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>urinary problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"All drugs and placebo were identical in appearance and taste." No further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Gwynne P, Hundziak M, Kavtschitsch J, Lefton M, Pasamanick B</allAuthors>
            <date>1962</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>451-5</pages>
            <title>Efficacy of trifluoperazine on withdrawal in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>134</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Gwynne P, Hundziak M, Kavtschitsch J, Lefton M, Pasamanick B</allAuthors>
            <date>1962</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>451-5</pages>
            <title>Efficacy of trifluoperazine on withdrawal in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>134</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Gwynne P, Hundziak M, Kavtschitsch J, Lefton M, Pasamanick B</references>
        <references>Efficacy of trifluoperazine on withdrawal in chronic schizophrenia</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1962</references>
        <references>134</references>
        <references></references>
        <references>451-5</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No means and SDs reported for MSRPP.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Gwynne-1962</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Three groups of 26 patients each (13 males and 13 females) were formed by random selection from the basic group" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>INPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1962</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"The three patients who developed jaundice were eliminated from the project".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Hall1955</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind", "the participating technicians, psychiatrists and psychologist recorded their judgments as the whether the patient received drug or placebo", "the psychiatrists and psychologist were neither completely "blind" nor completely "unblind".</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>56</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>72</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Hall</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Smith, Kline &amp; French Laboratories provided chlorpromazine, partly supported the study with a grant for statistical analysis and provided other assistance.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>56</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>72</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>65</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>34</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>liver problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>56</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>72</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>65</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>56</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>72</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>65</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>56</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>72</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>65</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>56</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>87</Intervention_Total>
            <Control_Events>72</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>88</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "identical-appearing placebo".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hollister LE, Hall RA</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>211-2</pages>
            <title>Phenothiazine derivatives and morphologic changes in the liver</title>
            <type>Journal article</type>
            <volume>123</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hall RA, Dunlap DJ</allAuthors>
            <date>1955</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>301-14</pages>
            <title>A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics</title>
            <type>Journal article</type>
            <volume>122</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hollister LE, Hall RA</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>211-2</pages>
            <title>Phenothiazine derivatives and morphologic changes in the liver</title>
            <type>Journal article</type>
            <volume>123</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Hall RA, Dunlap DJ</references>
        <references>A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1955</references>
        <references>122</references>
        <references></references>
        <references>301-14</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hollister LE, Hall RA</references>
        <references>Phenothiazine derivatives and morphologic changes in the liver</references>
        <references>American Journal of Psychiatry</references>
        <references>1966</references>
        <references>123</references>
        <references></references>
        <references>211-2</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>There were no useable data for specific symptoms and liver biopsy data was only reported for a non-random subset of participants.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hall-1955</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"The drug manufacturer supplied the material in 10 coded batches. Half of the batches contained drug, and half placebo (terra alba), and code letters were assigned at random to these batches. In turn, these codes letters were assigned in serial fashion to.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomised selection" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1955</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Of the 44 patients evaluated, 11 were dropped from the study during the 5 day period. OF the 111 dropped patients, 6 were in the drug group and 5 in the placebo group." Reasons for leaving the study early balanced across groups.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Hamill1975</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Hamill</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported. Placebo provided by Smith Kline &amp; French Laboratories, Philadelphia, Pa.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement> No information reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hamill WT, Fontana AF</allAuthors>
            <date>1975</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1023-6</pages>
            <title>The immediate effects of chlorpromazine in newly admitted schizophrenic patients</title>
            <type>Journal article</type>
            <volume>132</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hamill WT, Fontana AF</allAuthors>
            <date>1975</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1023-6</pages>
            <title>The immediate effects of chlorpromazine in newly admitted schizophrenic patients</title>
            <type>Journal article</type>
            <volume>132</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hamill WT, Fontana AF</references>
        <references>The immediate effects of chlorpromazine in newly admitted schizophrenic patients</references>
        <references>American Journal of Psychiatry</references>
        <references>1975</references>
        <references>132</references>
        <references></references>
        <references>1023-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No useable data reported for the BPRS and NOSIE and no SDs reported for CGI.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hamill-1975</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Patients were given a number from 1 to 44 according to the randomisation and without the participation of the research psychiatrist".</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Assignment of patients to the chlorpromazine or the placebo group was determined using a table of random numbers".</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1975</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Hamilton1960</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo>2 x 3</designAddedInfo>
        <designProse>Design: factorial (2 x 3)</designProse>
        <detectionBiasJudgement>"Form the point of view of the patients, nurses and physicians, there were 27 patients receiving one kind of tablet and 27 patients receiving the other kind, but only the pharmacist knew which of the patients were receiving active and which inert tablets.", "The patients were assessed on Behaviour in the ward by the charge nurses and on Symtoms by the physician".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </dobj>
        <mainAuthor>Hamilton</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Form the point of view of the patients, nurses and physicians, there were 27 patients receiving one kind of tablet and 27 patients receiving the other kind, but only the pharmacist knew which of the patients were receiving active and which inert tablets. All the tablets were sugar-coated nad the placebo tablets were indistinguishable from the active drugs. ".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hamilton M, Smith A, Lapidus HR, Cadogan EP</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>40-55</pages>
            <title>A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>106</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hamilton M, Smith A, Lapidus HR, Cadogan EP</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>40-55</pages>
            <title>A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>106</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hamilton M, Smith A, Lapidus HR, Cadogan EP</references>
        <references>A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics</references>
        <references>British Journal of Psychiatry</references>
        <references>1960</references>
        <references>106</references>
        <references></references>
        <references>40-55</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No means and SDs reported for mental state and a nurse-rated behaviour scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hamilton-1960</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Pharmacist [...] randomly selected" groups, no further details reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"The patients were randomly allotted to 6 groups of 9 patients each", "Each of these 3 groups was randomly coupled with another group, and the names of the patients in the 3 pairs of groups given to the hospital pharmacist. He randomly selected one pair of no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>FACTORIAL</trialDesign>
        <year>1960</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Of 174 patients starting in the project, 134 completed the two-week drug trial. The 40 patients who failed to complete the study usually did not return for appointments. An occasional patient in this total of 40 was dropped for reasons of protocol violation" .</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Hankoff1962</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>65</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>68</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Hankoff</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement>Supported by a grant from the US Public Health Service.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>65</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>68</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>25</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>95</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>25</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>72</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>25</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>72</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>ataxia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>25</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>72</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>25</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>72</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>25</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>72</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>nausea/vomiting</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>65</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>68</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>65</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>68</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>65</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>68</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>65</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>68</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "All the drugs and their placebos were administered in pink No.2 capsules".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hankoff LD, Rudorfer L, Paley HM</allAuthors>
            <date>1962</date>
            <issue></issue>
            <journalName>Journal of New Drugs</journalName>
            <originalTitle></originalTitle>
            <pages>173-8</pages>
            <title>A reference study of ataraxics. A two-week double blind outpatient evaluation</title>
            <type>Journal article</type>
            <volume>2</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hankoff LD, Rudorfer L, Paley HM</allAuthors>
            <date>1962</date>
            <issue></issue>
            <journalName>Journal of New Drugs</journalName>
            <originalTitle></originalTitle>
            <pages>173-8</pages>
            <title>A reference study of ataraxics. A two-week double blind outpatient evaluation</title>
            <type>Journal article</type>
            <volume>2</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hankoff LD, Rudorfer L, Paley HM</references>
        <references>A reference study of ataraxics. A two-week double blind outpatient evaluation</references>
        <references>Journal of New Drugs</references>
        <references>1962</references>
        <references>2</references>
        <references></references>
        <references>173-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for Manifest Anxiety and Affect Adjective Checklist.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hankoff-1962</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Patients were randomly assigned to treatment groups" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>COMMUNITY</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1962</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"It was necessary to discontinue medication during the third week on one patient in the treatment group because of the development of severe angioneurotic edema. This patient was eliminated from the project".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Hine1958</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind", "The results of this assignment were not known to the judges, raters or other ward personnel".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Hine</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Drugs provided by Smith Kline &amp; French Laboratories.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>weakness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "The results of this assignment were not known to the judges, raters or other ward personnel", "corresponding placebo tablets or solution" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hine FR</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Diseases</journalName>
            <originalTitle></originalTitle>
            <pages>220-7</pages>
            <title>Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic</title>
            <type>Journal article</type>
            <volume>127</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hine FR</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Diseases</journalName>
            <originalTitle></originalTitle>
            <pages>220-7</pages>
            <title>Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic</title>
            <type>Journal article</type>
            <volume>127</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hine FR</references>
        <references>Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic</references>
        <references>Journal of Nervous and Mental Diseases</references>
        <references>1958</references>
        <references>127</references>
        <references></references>
        <references>220-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No data reported for the Southeast Louisiana Hospital Behavior Rating Scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hine-1958</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Matched pairs" based on withdrawal symptoms "and one member of this pair was assigned to the treatment group by the toss of a coin.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1958</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> Losses to follow-up not clearly reported. Reasons for leaving the study early reported, but not according to group.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Hogarty1973</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo>2 x 2</designAddedInfo>
        <designProse>Design: factorial (2 x 2)</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>192</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>182</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>&gt;2 - 5 years</Subgroup>
        </dobj>
        <mainAuthor>Hogarty</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by grants from the Psychopharmacology Research Branch, National Institute of Mental Health (NIMH)., Chlorpromazine  was supplied by Smith Kline &amp; French Laboratories, Philadelphia.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>70</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>192</Intervention_Total>
            <Control_Events>131</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>182</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>long term (6 months - 2 years)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>99</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>192</Intervention_Total>
            <Control_Events>149</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>182</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>2 - 5 years</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>192</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>182</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>long term (&gt;6 months - 2 years)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>192</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>182</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>&gt;2 - 5 years</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Assigned on a double-blind basis to identical looking 100 mg or 50 mg tablets of chlorpromazine or placebo".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hogarty GE, Munetz MR</allAuthors>
            <date>1984</date>
            <issue></issue>
            <journalName>Journal of Clinical Psychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>17-24</pages>
            <title>Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate</title>
            <type>Journal article</type>
            <volume>4</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Goldberg S, Schooler N, Hogarty G, Roper M</allAuthors>
            <date>1977</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>171-84</pages>
            <title>Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy</title>
            <type>Journal article</type>
            <volume>34</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hogarty G, Goldberg S, Schooler N, Ulrich R</allAuthors>
            <date>1974</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>603-8</pages>
            <title>Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates</title>
            <type>Journal article</type>
            <volume>31</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hogarty G, Goldberg S, Schooler N</allAuthors>
            <date>1974</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>609-18</pages>
            <title>Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients</title>
            <type>Journal article</type>
            <volume>31</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hogarty G, Goldberg S</allAuthors>
            <date>1973</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>54-64</pages>
            <title>Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates</title>
            <type>Journal article</type>
            <volume>28</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hogarty G, Ulrich R</allAuthors>
            <date>1977</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>297-301</pages>
            <title>Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients</title>
            <type>Journal article</type>
            <volume>34</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hogarty GE, Munetz MR</allAuthors>
            <date>1984</date>
            <issue></issue>
            <journalName>Journal of Clinical Psychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>17-24</pages>
            <title>Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate</title>
            <type>Journal article</type>
            <volume>4</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Goldberg S, Schooler N, Hogarty G, Roper M</references>
        <references>Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy</references>
        <references>Archives of General Psychiatry</references>
        <references>1977</references>
        <references>34</references>
        <references></references>
        <references>171-84</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hogarty G, Goldberg S, Schooler N, Ulrich R</references>
        <references>Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates</references>
        <references>Archives of General Psychiatry</references>
        <references>1974</references>
        <references>31</references>
        <references></references>
        <references>603-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hogarty G, Goldberg S, Schooler N</references>
        <references>Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients</references>
        <references>Archives of General Psychiatry</references>
        <references>1974</references>
        <references>31</references>
        <references></references>
        <references>609-18</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Hogarty G, Goldberg S</references>
        <references>Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates</references>
        <references>Archives of General Psychiatry</references>
        <references>1973</references>
        <references>28</references>
        <references></references>
        <references>54-64</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hogarty G, Ulrich R</references>
        <references>Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients</references>
        <references>Archives of General Psychiatry</references>
        <references>1977</references>
        <references>34</references>
        <references></references>
        <references>297-301</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Hogarty GE, Munetz MR</references>
        <references>Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate</references>
        <references>Journal of Clinical Psychopharmacology</references>
        <references>1984</references>
        <references>4</references>
        <references></references>
        <references>17-24</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Number of deaths and number of participants in trouble with police not reported by group., No SDs reported for BPRS, Symptom Checklist, IMPS, Springfield Symptom Inventory, Major Role Adjustment Inventory, Katz Adjustment Scale, Casework Evaluation Schedu.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hogarty-1973</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>COMMUNITY</setting>
        <trialDesign>FACTORIAL</trialDesign>
        <year>1973</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Klein1973</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>46</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>42</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Klein</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported in part by grants from the Public Health Service of the National Institue of Mental Health., Smith Kline &amp; French Laboratories and Wellcome and Co supplied the drugs.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>46</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>42</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "Medication was administered in a highly flavoured liquid placebo, and each patient received a constant 40 ml/day from individually labelled bottles".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Klein D, Rosen B</allAuthors>
            <date>1973</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>480-5</pages>
            <title>Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients</title>
            <type>Journal article</type>
            <volume>29</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Klein D, Rosen B</allAuthors>
            <date>1973</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>480-5</pages>
            <title>Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients</title>
            <type>Journal article</type>
            <volume>29</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Klein D, Rosen B</references>
        <references>Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients</references>
        <references>Archives of General Psychiatry</references>
        <references>1973</references>
        <references>29</references>
        <references></references>
        <references>480-5</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for MSRPP.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Klein-1973</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1973</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Those patients whom data were incomplete, together with, those not receiving medication for at least ten days, were excluded from the study"., "Of the 238 patients who met all population restrictions, 187 remained  in the project at least 10 days [...] Fifty-nine patients completed the prescribed six-week treatment course."</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Kurland1961</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind", "Ratings were blind, in that raters did not know which drug the patients was receiving".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Kurland</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement>Funded by a research grant from the National Advisory Mental Health Council, National Institute of Health, US Public Health Service., Drugs provided by Smith Kline &amp; French Laboratories, Squibb Laboratories, Shering Corporation and Warner-Chilcott Laboratories.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>24</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>63</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>acute movement disorders (dystonia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>nausea/vomiting</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>acute - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>33</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "The drugs were dispensed in standard unmarked capsules [...] coloured pink to mask all identifying consistencies and colours of the drugs".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Kurland AA, Sutherland GF</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>Psychosomatics</journalName>
            <originalTitle></originalTitle>
            <pages>192-4</pages>
            <title>The phenothiazine tranquilizers - their neurological complications and significance</title>
            <type>Journal article</type>
            <volume>1</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AL</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>1-18</pages>
            <title>The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness</title>
            <type>Journal article</type>
            <volume>133</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Kurland AA, Hanlon TE, Tatom MH, Simopoulos AL</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Disease</journalName>
            <originalTitle></originalTitle>
            <pages>61-74</pages>
            <title>Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations</title>
            <type>Journal article</type>
            <volume>132</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Kurland AA, Nilsson GL, Hanlon TE</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1028-9</pages>
            <title>Pre-admission drug treatment of state psychiatric hospital patients</title>
            <type>Journal article</type>
            <volume>115</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Kurland AA, Sutherland GF</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>Psychosomatics</journalName>
            <originalTitle></originalTitle>
            <pages>192-4</pages>
            <title>The phenothiazine tranquilizers - their neurological complications and significance</title>
            <type>Journal article</type>
            <volume>1</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AL</references>
        <references>The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1961</references>
        <references>133</references>
        <references></references>
        <references>1-18</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kurland AA, Hanlon TE, Tatom MH, Simopoulos AL</references>
        <references>Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations</references>
        <references>Journal of Nervous and Mental Disease</references>
        <references>1961</references>
        <references>132</references>
        <references></references>
        <references>61-74</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kurland AA, Nilsson GL, Hanlon TE</references>
        <references>Pre-admission drug treatment of state psychiatric hospital patients</references>
        <references>American Journal of Psychiatry</references>
        <references>1959</references>
        <references>115</references>
        <references></references>
        <references>1028-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kurland AA, Sutherland GF</references>
        <references>The phenothiazine tranquilizers - their neurological complications and significance</references>
        <references>Psychosomatics</references>
        <references>1960</references>
        <references>1</references>
        <references></references>
        <references>192-4</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for the MSRPP, Psychotic Reaction Profile and Psychiatric Scale of Target Symptoms.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Kurland-1961</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"The choice of the particular drug to be used in any case was based on a predetermined random selection" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1961</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Of the 30 patients who initially fulfilled out conditions, one died from a cerebrovascular accident during the period of preliminary observations, and a second was eliminated because of slow phasic changes in mental state". Two losses to follow-up, but unclear is before or after randomisation.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Letemendia1967</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: cross-over</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Letemendia</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement> Supported by a grant from the Rockefeller foundation.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>14</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "Neither patients, doctors, nor nurses knew which patients were being given chlorpromazine and which placebo. All medication was dispensed in uniform amber-coloured capsules. Each patient was supplied from a separated bottle, replenished weekly according to the design by an independent party".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Letemendia F, Harris AD</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>950-8</pages>
            <title>Chlorpromazine and the untreated chronic schizophrenic: a long-term trial</title>
            <type>Journal article</type>
            <volume>113</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Letemendia F, Harris AD</allAuthors>
            <date>1967</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>950-8</pages>
            <title>Chlorpromazine and the untreated chronic schizophrenic: a long-term trial</title>
            <type>Journal article</type>
            <volume>113</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Letemendia F, Harris AD</references>
        <references>Chlorpromazine and the untreated chronic schizophrenic: a long-term trial</references>
        <references>British Journal of Psychiatry</references>
        <references>1967</references>
        <references>113</references>
        <references></references>
        <references>950-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs reported for mental state and behaviour scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Letemendia-1967</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Groups matched according to age, length of hospital stay and severity, "The designation of the two groups was determined by tossing a coin".</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>CROSSOVER</trialDesign>
        <year>1967</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Then nine patients were dropped from the study for various reasons. These reasons included: failure to report to the hospital for scheduled appointments (N=3); admissions to other hospitals (N=2); strong requests from the patient not to change the previous drugs (N=3); and a suicide after admission to the hospital (N=1)". Number of participants and reasons for leaving the study early not reported by groups.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Nishikawa1982</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>Japan</countries>
        <designAddedInfo>Data reported for first arm only</designAddedInfo>
        <designProse>Design: cross-over, data reported for first arm only</designProse>
        <detectionBiasJudgement>"Double-bind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </dobj>
        <mainAuthor>Nishikawa</mainAuthor>
        <meerKatCountry>Japan</meerKatCountry>
        <otherBiasJudgement> Drugs provided by SMP (Sankyo, Japan).</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>long term (6 months - 2 years)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>9</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>2 - 5 years</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Relapse (9 wks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Relapse (9 wks-6 Months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>10</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "Drug appearance, with respect to powder colour, taste and volume, was  made identical by adding a kind of stomachics.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y</allAuthors>
            <date>1982</date>
            <issue></issue>
            <journalName>Psychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>301-4</pages>
            <title>Prophylactic effect of neuroleptics in symptom-free schizophrenics</title>
            <type>Journal article</type>
            <volume>77</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y</allAuthors>
            <date>1982</date>
            <issue></issue>
            <journalName>Psychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>301-4</pages>
            <title>Prophylactic effect of neuroleptics in symptom-free schizophrenics</title>
            <type>Journal article</type>
            <volume>77</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y</references>
        <references>Prophylactic effect of neuroleptics in symptom-free schizophrenics</references>
        <references>Psychopharmacology</references>
        <references>1982</references>
        <references>77</references>
        <references></references>
        <references>301-4</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Not all expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Nishikawa-1982</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further information reported.</selectionBiasRandomSequenceJudgement>
        <setting>OUTPATIENT</setting>
        <trialDesign>CROSSOVER</trialDesign>
        <year>1982</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> Did not report any losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Payne1960</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>Canada</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </dobj>
        <mainAuthor>Payne</mainAuthor>
        <meerKatCountry>Canada</meerKatCountry>
        <otherBiasJudgement> Drugs supplied by ER Squibb and Sons of Canada, Limited., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>7</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>7</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "All three types of tablet were exactly the same colour, size and shape. Each patient's medication was supplied to the wards in identical containers bearing the patient's name only. The physician and ward personnel were unaware of which patient was receiving which tablet; the latter being known only to the pharmacist and not divulged until the completion of the investigation".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Payne P</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>Manitoba Medical Review</journalName>
            <originalTitle></originalTitle>
            <pages>196-8</pages>
            <title>A comparison of trifluopromazine, chlorpromazine and a placebo in twenty-one chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume></volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Payne P</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>Manitoba Medical Review</journalName>
            <originalTitle></originalTitle>
            <pages>196-8</pages>
            <title>A comparison of trifluopromazine, chlorpromazine and a placebo in twenty-one chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume></volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Payne P</references>
        <references>A comparison of trifluopromazine, chlorpromazine and a placebo in twenty-one chronic schizophrenic patients</references>
        <references>Manitoba Medical Review</references>
        <references>1960</references>
        <references></references>
        <references></references>
        <references>196-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Results for categories of 'improved', 'much improved' and 'unimproved' not fully reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Payne-1960</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"The patients were divided into three groups of seven persons" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1960</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> 6 patients left the study early from the propanolol and chlorpromazine groups, and 9 from the placebo group. Reasons for loss evenly distributes across groups.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Peet1981</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </dobj>
        <mainAuthor>Peet</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Relapse (9 wks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Relapse (9 wks-6 Months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Relapse (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>18</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "Capsules of identical appearance".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, et al</allAuthors>
            <date>1981</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>105-11</pages>
            <title>Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo</title>
            <type>Journal article</type>
            <volume>139</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, et al</allAuthors>
            <date>1981</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>105-11</pages>
            <title>Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo</title>
            <type>Journal article</type>
            <volume>139</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, et al</references>
        <references>Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo</references>
        <references>British Journal of Psychiatry</references>
        <references>1981</references>
        <references>139</references>
        <references></references>
        <references>105-11</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No means or SDs reported for IMPS, NOSIE and Discharge Readiness Inventory.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Peet-1981</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1981</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"The placebo group had the highest percentage of dropout (38%), followed by the high dose group (25%), and the low dose group (15%). Terminations due to side effects were most frequent in the high dose group, while the placebo group had the highest incidence of dropouts due to deteriorated behavior." Losses to follow-up balanced across intervention groups, with similar reasons for missing data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Prien1968</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>330</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>192</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Prien</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> The study appears to be free of other sources of bias.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>39</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>85</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>380</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>205</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>298</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>186</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>83</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>81</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>37</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>21</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>acute movement disorders (dystonia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>50</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>28</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>34</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>110</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>fits / loss of consciousness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>42</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>17</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>50</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>photosensitivity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>97</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>eye opacity / eye pigment problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>52</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>15</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>19</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>urinary problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>23</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>nausea/vomiting</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>salivation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>39</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>85</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Relapse (9 wks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>330</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>192</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>37</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>208</Intervention_Total>
            <Control_Events>85</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Relapse (9 wks-6 Months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>27</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>208</Intervention_Total>
            <Control_Events>85</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Relapse (9 wks-6 Months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>187</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>208</Intervention_Total>
            <Control_Events>205</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>193</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>208</Intervention_Total>
            <Control_Events>205</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>208</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Behaviour 1. Deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>27</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>208</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Behaviour 1. Deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>39</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>85</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>330</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>192</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>298</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>186</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 3. Severity of illness (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>37</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>330</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>192</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>37</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>70</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>330</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>416</Intervention_Total>
            <Control_Events>192</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>212</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Prien RF, Levine J, Cole JO</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>739-45</pages>
            <title>Indications for high dose chlorpromazine therapy in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>31</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Crane GE</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Agressologie</journalName>
            <originalTitle></originalTitle>
            <pages>209-18</pages>
            <title>Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs</title>
            <type>Journal article</type>
            <volume>2</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>De Long SL</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>19-22</pages>
            <title>Incidence and significance of chlorpromazine-induced eye changes</title>
            <type>Journal article</type>
            <volume>29</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Gardos G, Cole JO, LaBrie RA</allAuthors>
            <date>1982</date>
            <issue></issue>
            <journalName>Hospital and Community Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>983-4</pages>
            <title>A 12-year follow-up study of chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>33</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Mandel A, Gross M</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>32-6</pages>
            <title>Agranulocyctosis and phenothiazines</title>
            <type>Journal article</type>
            <volume>29</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Prien R, Cole JO</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>482-95</pages>
            <title>High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group</title>
            <type>Journal article</type>
            <volume>18</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Prien R, DeLong S, Cole J, Levine J</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>464-8</pages>
            <title>Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study</title>
            <type>Journal article</type>
            <volume>23</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Prien RF, Cole JO, Belkin NF</allAuthors>
            <date>1968</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>679-86</pages>
            <title>Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication</title>
            <type>Journal article</type>
            <volume>115</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Prien RF, Levine J, Cole JO</allAuthors>
            <date>1970</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>739-45</pages>
            <title>Indications for high dose chlorpromazine therapy in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>31</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Crane GE</references>
        <references>Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs</references>
        <references>Agressologie</references>
        <references>1968</references>
        <references>2</references>
        <references></references>
        <references>209-18</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>De Long SL</references>
        <references>Incidence and significance of chlorpromazine-induced eye changes</references>
        <references>Diseases of the Nervous System</references>
        <references>1968</references>
        <references>29</references>
        <references></references>
        <references>19-22</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Gardos G, Cole JO, LaBrie RA</references>
        <references>A 12-year follow-up study of chronic schizophrenics</references>
        <references>Hospital and Community Psychiatry</references>
        <references>1982</references>
        <references>33</references>
        <references></references>
        <references>983-4</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Mandel A, Gross M</references>
        <references>Agranulocyctosis and phenothiazines</references>
        <references>Diseases of the Nervous System</references>
        <references>1968</references>
        <references>29</references>
        <references></references>
        <references>32-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Prien R, Cole JO</references>
        <references>High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group</references>
        <references>Archives of General Psychiatry</references>
        <references>1968</references>
        <references>18</references>
        <references></references>
        <references>482-95</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Prien R, DeLong S, Cole J, Levine J</references>
        <references>Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study</references>
        <references>Archives of General Psychiatry</references>
        <references>1970</references>
        <references>23</references>
        <references></references>
        <references>464-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Prien RF, Cole JO, Belkin NF</references>
        <references>Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication</references>
        <references>British Journal of Psychiatry</references>
        <references>1968</references>
        <references>115</references>
        <references></references>
        <references>679-86</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Prien RF, Levine J, Cole JO</references>
        <references>Indications for high dose chlorpromazine therapy in chronic schizophrenia</references>
        <references>Diseases of the Nervous System</references>
        <references>1970</references>
        <references>31</references>
        <references></references>
        <references>739-45</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SD for IMPS, NOSIE, Discharge Readiness Inventory.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Prien-1968</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1968</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Out of 136 patients 108 who have completed the treatment for a period of 2 months were taken for final assessment. The remaining 28 were dropouts for reasons of escape and leaving without medical advice". Number randomised to each group not reported. Number lost from each group not reported.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Ramu1999</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>India</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Ramu</mainAuthor>
        <meerKatCountry>India</meerKatCountry>
        <otherBiasJudgement>Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>1990 to 2002 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>27</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>27</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "The medicines and placebo were administered in the form of identical tablets".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="bookSectionReferenceObject">
            <allAuthors>Ramu MG, Chaturvedi DD, Venkataram BS, Shankara MR, Leelavathy S, Janakiramiah N, et al</allAuthors>
            <bookName>Ayurvedic Management of Unmada (Schizophrenia)</bookName>
            <city>New Delhi</city>
            <date>1999</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages>59-76</pages>
            <publisher>Central Council for Research in Ayurveda &amp; Siddha</publisher>
            <title>A double blind controlled study on the role of brahmyadiyoga and tagara in navonmada (acute schizophrenia)</title>
            <type>Book section</type>
            <volume></volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="bookSectionReferenceObject">
            <allAuthors>Ramu MG, Chaturvedi DD, Venkataram BS, Shankara MR, Leelavathy S, Janakiramiah N, et al</allAuthors>
            <bookName>Ayurvedic Management of Unmada (Schizophrenia)</bookName>
            <city>New Delhi</city>
            <date>1999</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages>59-76</pages>
            <publisher>Central Council for Research in Ayurveda &amp; Siddha</publisher>
            <title>A double blind controlled study on the role of brahmyadiyoga and tagara in navonmada (acute schizophrenia)</title>
            <type>Book section</type>
            <volume></volume>
        </referenceList>
        <references>BOOK_SECTION</references>
        <references>NO</references>
        <references>Ramu MG, Chaturvedi DD, Venkataram BS, Shankara MR, Leelavathy S, Janakiramiah N, et al</references>
        <references>A double blind controlled study on the role of brahmyadiyoga and tagara in navonmada (acute schizophrenia)</references>
        <references>Ayurvedic Management of Unmada (Schizophrenia)</references>
        <references>1999</references>
        <references></references>
        <references></references>
        <references>59-76</references>
        <references></references>
        <references></references>
        <references></references>
        <references>Central Council for Research in Ayurveda &amp; Siddha</references>
        <references>New Delhi</references>
        <references></references>
        <reportingBiasJudgement>Not all expected outcomes reported., Unclear which rating scales are reported in the results tables.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Ramu-1999</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly allocated" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>OUTPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1999</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"78 cases were taken for the study. Of them, 13 cases were dropped out for various reasons" N randomised to each group not reported. Reasons for losses and number of losses to follow-up per group not reported.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Ramu1999a</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>India</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>not stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Ramu</mainAuthor>
        <meerKatCountry>India</meerKatCountry>
        <otherBiasJudgement>Drugs supplied by M/s Eros Pharma, Bangalore.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>1990 to 2002 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>not stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "Sugar coated uniform tablets of the trial drugs" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="bookSectionReferenceObject">
            <allAuthors>Ramu MG, Chaturvedi DD, Venkataram BS, Shankara MR, Leelavathy S, Janakiramiah N, et al</allAuthors>
            <bookName>Ayurvedic Management of Unmada (Schizophrenia)</bookName>
            <city>New Delhi</city>
            <date>1999</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages>77-88</pages>
            <publisher>Central Council for Research in Ayurveda &amp; Siddha</publisher>
            <title>A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia)</title>
            <type>Book section</type>
            <volume></volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="bookSectionReferenceObject">
            <allAuthors>Ramu MG, Chaturvedi DD, Venkataram BS, Shankara MR, Leelavathy S, Janakiramiah N, et al</allAuthors>
            <bookName>Ayurvedic Management of Unmada (Schizophrenia)</bookName>
            <city>New Delhi</city>
            <date>1999</date>
            <edition></edition>
            <editor></editor>
            <originalTitle></originalTitle>
            <pages>77-88</pages>
            <publisher>Central Council for Research in Ayurveda &amp; Siddha</publisher>
            <title>A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia)</title>
            <type>Book section</type>
            <volume></volume>
        </referenceList>
        <references>BOOK_SECTION</references>
        <references>NO</references>
        <references>Ramu MG, Chaturvedi DD, Venkataram BS, Shankara MR, Leelavathy S, Janakiramiah N, et al</references>
        <references>A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia)</references>
        <references>Ayurvedic Management of Unmada (Schizophrenia)</references>
        <references>1999</references>
        <references></references>
        <references></references>
        <references>77-88</references>
        <references></references>
        <references></references>
        <references></references>
        <references>Central Council for Research in Ayurveda &amp; Siddha</references>
        <references>New Delhi</references>
        <references></references>
        <reportingBiasJudgement>N not reported for psychiatric rating scale. Total scores not reported for final assessment of psychiatric rating scale., N reported for global improvement differs from N reported in each group.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Ramu-1999a</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>High risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement> No information reported.</selectionBiasRandomSequenceJudgement>
        <setting>NOTAVAILABLE</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1999</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"The 80 patients in this study represented 63% of the total sample (127) studied while in the hospital. It was noted that during the follow-up period, there was a significantly larger attrition of subjects from the  group assigned to placebo while in the hospital than the group assigned to chlorpromazine (45% vs 26%)."</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Rappaport1978</authorYearLetter>
        <blindingMethod>SINGLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Ratings were made by a trained research assistant who was unaware as  to what the patient's medication condition was while he was hospitalised".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>44</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </dobj>
        <mainAuthor>Rappaport</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported California Department of Mental Hygiene and the National  Institute of Mental Health and from the Wickes Foundation and Esalen Institute.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>44</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>33</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>44</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>acute - Relapse (9 wks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>53</Intervention_Total>
            <Control_Events>44</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>74</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Relapse (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"physician [...] and the nursing staff remained blind as to whether the patient was receiving medication or placebos" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J</allAuthors>
            <date>1978</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>100-11</pages>
            <title>Are there schizophrenics for whom drugs may be unnecessary or contraindicated?</title>
            <type>Journal article</type>
            <volume>13</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J</allAuthors>
            <date>1978</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>100-11</pages>
            <title>Are there schizophrenics for whom drugs may be unnecessary or contraindicated?</title>
            <type>Journal article</type>
            <volume>13</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J</references>
        <references>Are there schizophrenics for whom drugs may be unnecessary or contraindicated?</references>
        <references>International Pharmacopsychiatry</references>
        <references>1978</references>
        <references>13</references>
        <references></references>
        <references>100-11</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Unclear when outcomes recorded. Not all expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Rappaport-1978</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Assigned randomly" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1978</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Six patients had to be excluded from the investigation as they were given ECT. Of these subjects two were on trifluoroperazine, one on chlorpromazine and three were controls"., "An additional three subjects, one from each group, had to be removed from the study because of transfer or home leave".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Reardon1966</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Neither the ward personnel nor the investigator knew which drug the patient received" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Reardon</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Smith Kline and French provided drugs., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>acute - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>11</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Neither the ward personnel nor the investigator knew which drug the patient received" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Reardon JD, Abrams S</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>265-70</pages>
            <title>Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo)</title>
            <type>Journal article</type>
            <volume>27</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Reardon JD, Abrams S</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>265-70</pages>
            <title>Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo)</title>
            <type>Journal article</type>
            <volume>27</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Reardon JD, Abrams S</references>
        <references>Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo)</references>
        <references>Diseases of the Nervous System</references>
        <references>1966</references>
        <references>27</references>
        <references></references>
        <references>265-70</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No means or SDs reported for the MMPI. Not all expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Reardon-1966</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Randomly assigned trifluoroperazine, chlorpromazine or placebo by the pharmacy" no further details reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1966</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Reschke1974</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Reschke</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>10</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>11</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Reschke RW</allAuthors>
            <date>1974</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>112-5</pages>
            <title>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia</title>
            <type>Journal article</type>
            <volume>35</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Reschke RW</allAuthors>
            <date>1974</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>112-5</pages>
            <title>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia</title>
            <type>Journal article</type>
            <volume>35</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Reschke RW</references>
        <references>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia</references>
        <references>Diseases of the Nervous System</references>
        <references>1974</references>
        <references>35</references>
        <references></references>
        <references>112-5</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No means and SDs reported for BPRS.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Reschke-1974</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1974</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Saretsky1966</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Throughout the experiment, whether the patient received the drug or a placebo was not known to anyone connected with the experiment."</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Saretsky</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"The drugs were packaged in individual bottles with only the patient's name printed on them as a means of identification.", "Throughout the experiment, whether the patient received the drug or a placebo was not known to anyone connected with the experiment.", "The two kinds of pills were identical in size, shape, colour, and taste."</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Saretsky T</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>Journal of Abnormal Psychology</journalName>
            <originalTitle></originalTitle>
            <pages>247-52</pages>
            <title>Effects of chlorpromazine on primary-process thought manifestations</title>
            <type>Journal article</type>
            <volume>71</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Saretsky T</allAuthors>
            <date>1966</date>
            <issue></issue>
            <journalName>Journal of Abnormal Psychology</journalName>
            <originalTitle></originalTitle>
            <pages>247-52</pages>
            <title>Effects of chlorpromazine on primary-process thought manifestations</title>
            <type>Journal article</type>
            <volume>71</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Saretsky T</references>
        <references>Effects of chlorpromazine on primary-process thought manifestations</references>
        <references>Journal of Abnormal Psychology</references>
        <references>1966</references>
        <references>71</references>
        <references></references>
        <references>247-52</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Not all expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Saretsky-1966</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1966</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Only 2 patients were dropped [...] because their psychiatric condition became and remained worse.", "During the thirteenth week. a third patient who was in the trifluoperazine group eloped from the hospital." Only 43 participants took the MMPI three times.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Schiele1961</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </dobj>
        <mainAuthor>Schiele</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Behaviour: 2. Unchanged</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Behaviour: 2. Unchanged</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>rigidity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>weakness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>urinary problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blurred vision</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>salivation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un-cooperative</Outcome>
            <Subgroup>only men</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"During the first 16 weeks, the study was carried out under strict double-blind conditions. Each patient had his individual bottle of medication; the capsules were identical in appearance, and only the hospital pharmacist had the code for determining which patient was receiving each kind of medication".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Schiele BC, Vestre ND, Stein KE</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Journal of Clinical and Experiemental Psychopathology</journalName>
            <originalTitle></originalTitle>
            <pages>151-62</pages>
            <title>A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients</title>
            <type>Journal article</type>
            <volume>22</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Schiele BC, Vestre ND, Stein KE</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Journal of Clinical and Experiemental Psychopathology</journalName>
            <originalTitle></originalTitle>
            <pages>151-62</pages>
            <title>A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients</title>
            <type>Journal article</type>
            <volume>22</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Schiele BC, Vestre ND, Stein KE</references>
        <references>A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients</references>
        <references>Journal of Clinical and Experiemental Psychopathology</references>
        <references>1961</references>
        <references>22</references>
        <references></references>
        <references>151-62</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SD reported for the MBS.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Schiele-1961</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1961</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>"Four of the 57 subjects, three on CPZ, and one on PL,failed  to complete the 12 weeks of study. The PL subject and one CPZ  subject were terminated because of behavioural deterioration after 4 and 8 weeks respectively. The other two CPZ subjects developed intestinal obstruction secondary to massive fecal  impactions and were terminated in the 7th week of study."</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Serafetinides1972</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Serafetinides</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported in part by a US Public Health Service Grant.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>acute movement disorders (dystonia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>liver problems</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>photosensitivity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight increase</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>weight decrease</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 2. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>high - Behaviour 1. Deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>13</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 1. RANDOMISATION</Outcome>
            <Subgroup>stated - Global state: 1. No overall improvement (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"All medications were prepared in identically appearing capsules" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D</allAuthors>
            <date>1973</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>245-7</pages>
            <title>A method of quantifying EEG for psychopharmacological research</title>
            <type>Journal article</type>
            <volume>8</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Clark ML</allAuthors>
            <date>1973</date>
            <issue></issue>
            <journalName>Biological Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>263-7</pages>
            <title>Psychological effects of single dose antipsychotic medication</title>
            <type>Journal article</type>
            <volume>7</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Collins S, Clark ML</allAuthors>
            <date>1972</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Diseases</journalName>
            <originalTitle></originalTitle>
            <pages>31-42</pages>
            <title>Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives</title>
            <type>Journal article</type>
            <volume>154</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D, Clark ML</allAuthors>
            <date>1972</date>
            <issue></issue>
            <journalName>Journal of Nervous and Mental Diseases</journalName>
            <originalTitle></originalTitle>
            <pages>366-9</pages>
            <title>Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics</title>
            <type>Journal article</type>
            <volume>155</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Serafetinides EA, Willis D</allAuthors>
            <date>1973</date>
            <issue></issue>
            <journalName>International Pharmacopsychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>245-7</pages>
            <title>A method of quantifying EEG for psychopharmacological research</title>
            <type>Journal article</type>
            <volume>8</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Clark ML</references>
        <references>Psychological effects of single dose antipsychotic medication</references>
        <references>Biological Psychiatry</references>
        <references>1973</references>
        <references>7</references>
        <references></references>
        <references>263-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Collins S, Clark ML</references>
        <references>Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives</references>
        <references>Journal of Nervous and Mental Diseases</references>
        <references>1972</references>
        <references>154</references>
        <references></references>
        <references>31-42</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Willis D, Clark ML</references>
        <references>Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics</references>
        <references>Journal of Nervous and Mental Diseases</references>
        <references>1972</references>
        <references>155</references>
        <references></references>
        <references>366-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Serafetinides EA, Willis D</references>
        <references>A method of quantifying EEG for psychopharmacological research</references>
        <references>International Pharmacopsychiatry</references>
        <references>1973</references>
        <references>8</references>
        <references></references>
        <references>245-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs were reported for the CGI, NOSIE and the OBPRS., No data was reported for the psychological function tests.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Serafetinides-1972</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomly assigned" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1972</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Shepherd1956</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo>Latin square slightly modified - data extracted for first arm only</designAddedInfo>
        <designProse>Design: cross-over (Latin square, slightly modified) - data extracted for first arm only</designProse>
        <detectionBiasJudgement>"Weekly clinical assessments were carried out by one of us (DCW) who was unaware of the nature of individual prescriptions".</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Shepherd</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement> Messrs Ciba supplied serpasil and dummy tablets, Messrs May and Baker supplied dummy tablets.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>8</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Two kinds of inert substances were employed, one indistinguishable from reserpine, the other from chlorpromazine. Nobody but the ward doctor allocating the drugs and the dispenser knew which patients were receiving drugs and which patients were on placebo".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Shepherd M, Watt DC</allAuthors>
            <date>1956</date>
            <issue></issue>
            <journalName>Journal of Neurology, Neurosurgery and Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>232-5</pages>
            <title>A controlled clinical study of chlorpromazine and reserpine</title>
            <type>Journal article</type>
            <volume>19</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Shepherd M, Watt DC</allAuthors>
            <date>1956</date>
            <issue></issue>
            <journalName>Journal of Neurology, Neurosurgery and Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>232-5</pages>
            <title>A controlled clinical study of chlorpromazine and reserpine</title>
            <type>Journal article</type>
            <volume>19</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Shepherd M, Watt DC</references>
        <references>A controlled clinical study of chlorpromazine and reserpine</references>
        <references>Journal of Neurology, Neurosurgery and Psychiatry</references>
        <references>1956</references>
        <references>19</references>
        <references></references>
        <references>232-5</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Adverse effects were not reported for each individual arm.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Shepherd-1956</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>The 24 patients were divided into three groups of eight (A,B, and C) by random selection" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>CROSSOVER</trialDesign>
        <year>1956</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Simon1958</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Simon</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement> No information reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, et al</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1077-86</pages>
            <title>A controlled study of the short-term differential treatment of schizophrenia</title>
            <type>Journal article</type>
            <volume>114</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Simon W, Wirt AL, Wirt RD, Halloran AV</allAuthors>
            <date>1965</date>
            <issue></issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>510-5</pages>
            <title>Long-term follow-up study of schizophrenic patients</title>
            <type>Journal article</type>
            <volume>12</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, et al</allAuthors>
            <date>1958</date>
            <issue></issue>
            <journalName>American Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1077-86</pages>
            <title>A controlled study of the short-term differential treatment of schizophrenia</title>
            <type>Journal article</type>
            <volume>114</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Simon W, Wirt AL, Wirt RD, Halloran AV</references>
        <references>Long-term follow-up study of schizophrenic patients</references>
        <references>Archives of General Psychiatry</references>
        <references>1965</references>
        <references>12</references>
        <references></references>
        <references>510-5</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, et al</references>
        <references>A controlled study of the short-term differential treatment of schizophrenia</references>
        <references>American Journal of Psychiatry</references>
        <references>1958</references>
        <references>114</references>
        <references></references>
        <references>1077-86</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Means and SDs were not reported for the MMPI., No data was reported for the Scale of Occupational Adjustment.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Simon-1958</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Assigned to one of 4 treatment groups on a random basis [...] the staff was kept ignorant of the order within the random list".</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1958</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> Two participants lost to follow-up in the chlorpromazine group and two in the clordiazepoxide group, reasons for leaving the study early not reported. Unclear whether there were any losses in the placebo group.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Smith1961</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Neither the patients nor the attending physicians knew what medication was being given." no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </dobj>
        <mainAuthor>Smith</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement> Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Behaviour: 2. Unchanged</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>13</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"The medication used during the study was prepared in identical capsules", "Neither the patients nor the attending physicians knew what medication was being given. An identifying code was available but not broken until the end of the study."</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Smith ME</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Connecticut State Medical Journal</journalName>
            <originalTitle></originalTitle>
            <pages>153-7</pages>
            <title>A clinical study of chlorpromazine and chlordiazepoxide</title>
            <type>Journal article</type>
            <volume>25</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Smith ME</allAuthors>
            <date>1961</date>
            <issue></issue>
            <journalName>Connecticut State Medical Journal</journalName>
            <originalTitle></originalTitle>
            <pages>153-7</pages>
            <title>A clinical study of chlorpromazine and chlordiazepoxide</title>
            <type>Journal article</type>
            <volume>25</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Smith ME</references>
        <references>A clinical study of chlorpromazine and chlordiazepoxide</references>
        <references>Connecticut State Medical Journal</references>
        <references>1961</references>
        <references>25</references>
        <references></references>
        <references>153-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>All expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Smith-1961</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>The 45 patients were divided into three matched groups on the basis of age, illness duration and predominant symptomatology" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>NOTAVAILABLE</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1961</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Somerville1960</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>Australia</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement> No information reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Somerville</mainAuthor>
        <meerKatCountry>Australia</meerKatCountry>
        <otherBiasJudgement> Sandoz Australia Proprietary Limited and May &amp; Baker (Australia) Proprietary Limited supplied drugs., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Behaviour: 1. Deteriorated/ disturbed/un-cooperative</Outcome>
            <Subgroup>short term - (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>photosensitivity</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>dry mouth</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un-cooperative</Outcome>
            <Subgroup>only women</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Behaviour deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>5</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>23</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>30</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"The two placebos were identical in appearance with the respective active tablets."</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Somerville DM, Cohen PH, Graves GD</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1417-24</pages>
            <title>Phenothiazine side-effects. Comparison of two major tranquillizers</title>
            <type>Journal article</type>
            <volume>106</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Somerville DM, Cohen PH, Graves GD</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>1417-24</pages>
            <title>Phenothiazine side-effects. Comparison of two major tranquillizers</title>
            <type>Journal article</type>
            <volume>106</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Somerville DM, Cohen PH, Graves GD</references>
        <references>Phenothiazine side-effects. Comparison of two major tranquillizers</references>
        <references>British Journal of Psychiatry</references>
        <references>1960</references>
        <references>106</references>
        <references></references>
        <references>1417-24</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>All expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Somerville-1960</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"A doctor who had no duties connected with the ward concerned allotted each of the groups to a particular therapy" no further details reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Random choice" matched on symptoms, age, and duration of illness, no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1960</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> Losses to follow-up not reported.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Spohn1977</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>USA</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"During the drug treatment period, patients, project personnel, and hospital personnel were "blind" to the patients' drug status" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Relapse (0-8 wks)</Subgroup>
        </dobj>
        <mainAuthor>Spohn</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <otherBiasJudgement> Supported by a Public Health Service research grant and a research scientist award from the National Institute of Mental Health and by the Ittleson Family Foundation., Chlorpromazine supplied by Smith Kline and French Laboratories.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>Relapse</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>20</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Relapse (0-8 wks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"During the drug treatment period, patients, project personnel, and hospital personnel were "blind" to the patients' drug status" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Spohn H, Lacoursiere R, Thompson K, Coyne L</allAuthors>
            <date>1977</date>
            <issue>6</issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>633-44</pages>
            <title>Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>34</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Spohn H, Lacoursiere R, Thompson K, Coyne L</allAuthors>
            <date>1977</date>
            <issue>6</issue>
            <journalName>Archives of General Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>633-44</pages>
            <title>Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>34</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Spohn H, Lacoursiere R, Thompson K, Coyne L</references>
        <references>Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics</references>
        <references>Archives of General Psychiatry</references>
        <references>1977</references>
        <references>34</references>
        <references>6</references>
        <references>633-44</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Means and SDs were not reported for the Global Severity Scale, Global improvement Scale and the Ward Behaviour Rating Scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Spohn-1977</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Random assignment" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1977</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Tetreault1969</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>7.9</Control_Mean>
            <Control_SD>3.34</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>6.1</Intervention_Mean>
            <Intervention_SD>3.34</Intervention_SD>
            <Outcome>Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </cobj>
        <countries>Canada</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>nausea/vomiting</Subgroup>
        </dobj>
        <mainAuthor>Tetreault</mainAuthor>
        <meerKatCountry>Canada</meerKatCountry>
        <otherBiasJudgement> Partly supported by a grant-in-aid from Sandoz (Canada) Ltd.  who supplied the drugs.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>fits / loss of consciousness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>weakness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>blood problems (agranulocytosis, leukopenia)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>constipation</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>nausea/vomiting</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>48.2</Control_Mean>
            <Control_SD>7.64</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>42.5</Intervention_Mean>
            <Intervention_SD>7.64</Intervention_SD>
            <Outcome>Mental state: 2. Average endpoint scores (BPRS, high score=worse)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>48.9</Control_Mean>
            <Control_SD>9.88</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>41.2</Intervention_Mean>
            <Intervention_SD>9.88</Intervention_SD>
            <Outcome>Mental state: 2. Average endpoint scores (BPRS, high score=worse)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>17.4</Control_Mean>
            <Control_SD>5.36</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>14.5</Intervention_Mean>
            <Intervention_SD>5.36</Intervention_SD>
            <Outcome>Behaviour: 3. Average endpoint scores (RRS, high score=worse)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>21.4</Control_Mean>
            <Control_SD>6.8</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>16.8</Intervention_Mean>
            <Intervention_SD>6.8</Intervention_SD>
            <Outcome>Behaviour: 3. Average endpoint scores (RRS, high score=worse)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>8.5</Control_Mean>
            <Control_SD>2.55</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>7.1</Intervention_Mean>
            <Intervention_SD>2.55</Intervention_SD>
            <Outcome>Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Control_Mean>7.9</Control_Mean>
            <Control_SD>3.34</Control_SD>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>15</Intervention_Total>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Intervention_Mean>6.1</Intervention_Mean>
            <Intervention_SD>3.34</Intervention_SD>
            <Outcome>Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse)</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"TPS-23 (50mg, chlorpromazine (100 mg) and placebo presented in identical white capsules; they were distributed on the ward in containers on which only the patient's name appeared. The double-blind technique was followed throughout the experiment".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Tetreault L</allAuthors>
            <date>1969</date>
            <issue></issue>
            <journalName>Actualites Pharmacologiques</journalName>
            <originalTitle>Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique</originalTitle>
            <pages>221-8</pages>
            <title>Comparative study of two drugs and a placebo in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>22</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L</allAuthors>
            <date>1969</date>
            <issue>2</issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>74-84</pages>
            <title>Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>30</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Tetreault L</allAuthors>
            <date>1969</date>
            <issue></issue>
            <journalName>Actualites Pharmacologiques</journalName>
            <originalTitle>Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique</originalTitle>
            <pages>221-8</pages>
            <title>Comparative study of two drugs and a placebo in chronic schizophrenia</title>
            <type>Journal article</type>
            <volume>22</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L</references>
        <references>Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients</references>
        <references>Diseases of the Nervous System</references>
        <references>1969</references>
        <references>30</references>
        <references>2</references>
        <references>74-84</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Tetreault L</references>
        <references>Comparative study of two drugs and a placebo in chronic schizophrenia</references>
        <references>Actualites Pharmacologiques</references>
        <references>1969</references>
        <references>22</references>
        <references></references>
        <references>221-8</references>
        <references>Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>All expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Tetreault-1969</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Patients received one of the tested drugs according to a random number table".</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1969</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> Losses to follow-up not reported.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Vaughan1955</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries>UK</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"The hospital pharmacist alone knowing which patients were receiving chlorpromazine and which the placebo" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Vaughan</mainAuthor>
        <meerKatCountry>UK</meerKatCountry>
        <otherBiasJudgement> Messrs May &amp; Baker supplied the placebo tablets., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>19</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>24</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"The hospital pharmacist alone knowing which patients were receiving chlorpromazine and which the placebo" no further details reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Vaughan GF, Leiberman DM, Cook LC</allAuthors>
            <date>1955</date>
            <issue></issue>
            <journalName>Lancet</journalName>
            <originalTitle></originalTitle>
            <pages>1083-7</pages>
            <title>Chlorpromazine in psychiatry</title>
            <type>Journal article</type>
            <volume>1</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Vaughan GF, Leiberman DM, Cook LC</allAuthors>
            <date>1955</date>
            <issue></issue>
            <journalName>Lancet</journalName>
            <originalTitle></originalTitle>
            <pages>1083-7</pages>
            <title>Chlorpromazine in psychiatry</title>
            <type>Journal article</type>
            <volume>1</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Vaughan GF, Leiberman DM, Cook LC</references>
        <references>Chlorpromazine in psychiatry</references>
        <references>Lancet</references>
        <references>1955</references>
        <references>1</references>
        <references></references>
        <references>1083-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Not all expected outcomes reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Vaughan-1955</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"By random selection" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1955</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement> There were no losses to follow-up.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Walsh1959</authorYearLetter>
        <blindingMethod>NOTAVAILABLE</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Neither the doctor nor the ward staff were aware of the nature of the preparation being given to a particular patient" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Walsh</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>ER Squibb and Sons Ltd, London provided drugs., Source of funding not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Global state: 1a. No overall improvement (psychiatrist-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Adverse effects: 1. Movement disorders</Outcome>
            <Subgroup>parkinsonism (includes EPS)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Adverse effects: 3. Blood, skin, liver, eyes</Outcome>
            <Subgroup>rashes/itching/skin disorders</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>Adverse effects: 4. Other</Outcome>
            <Subgroup>blood pressure - low +/- dizziness/syncope</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>22</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>As this involved periodic changes in the number and/or size  of the tablets, the number and/or size of the tablets given to the placebo group was altered simultaneously. Neither the doctor nor the ward staff were aware of the nature of the preparation being given to a particular patient. A separate bottle was assigned to each patient and in this supplies of the specific preparation were issued at weekly intervals".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Walsh GP, Walton D, Black DA</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>199-209</pages>
            <title>The relative efficacy of "Vespral" and chlorpromazine in the treatment of a group of chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>105</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Walsh GP, Walton D, Black DA</allAuthors>
            <date>1959</date>
            <issue></issue>
            <journalName>British Journal of Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>199-209</pages>
            <title>The relative efficacy of "Vespral" and chlorpromazine in the treatment of a group of chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>105</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Walsh GP, Walton D, Black DA</references>
        <references>The relative efficacy of "Vespral" and chlorpromazine in the treatment of a group of chronic schizophrenic patients</references>
        <references>British Journal of Psychiatry</references>
        <references>1959</references>
        <references>105</references>
        <references></references>
        <references>199-209</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No SDs were reported for Rowell 'Psychoticism' Rating Scale and the Venables Activity-Withdrawal Rating Scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Walsh-1959</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement> No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Allocation of a preparation to a group was purely arbitrary", participants matched on age, hospitalisation, adjustment, psychotic behaviour, and activity/withdrawal. No further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1959</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>For the outcome global impression "the number [of participants] is less than 16 in the groups, because some patients refused to take their medication".</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Weckowicz1960</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>Canada</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>"Double-blind" no further details reported.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </dobj>
        <mainAuthor>Weckowicz</mainAuthor>
        <meerKatCountry>Canada</meerKatCountry>
        <otherBiasJudgement>Funded by the Rockefeller Foundation and the Federal Fund.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>Global state: 1b. No overall improvement (nurse-rated)</Outcome>
            <Subgroup>short term (0-8 weeks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>16</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>16</Control_Total>
            <Outcome>Adverse effects: 1. Central nervous system</Outcome>
            <Subgroup>sleepiness</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC</Outcome>
            <Subgroup>chronic - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE</Outcome>
            <Subgroup>low - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</Outcome>
            <Subgroup>no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007</Outcome>
            <Subgroup>Pre-1990 - Global state 1. No overall improvement (0-8 wks)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>14</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>15</Control_Total>
            <Outcome>SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA</Outcome>
            <Subgroup>not LOCF - Global state: 1. No overall improvement (0-8 weeks)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>"Double-blind", "The patients in the three groups received respectively from bottles marked "A", "B" and "C" 50mg tablets which looked exactly the same".</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Weckowicz TE, Ward T</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>527-8</pages>
            <title>Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>21</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Weckowicz TE, Ward T</allAuthors>
            <date>1960</date>
            <issue></issue>
            <journalName>Diseases of the Nervous System</journalName>
            <originalTitle></originalTitle>
            <pages>527-8</pages>
            <title>Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients</title>
            <type>Journal article</type>
            <volume>21</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Weckowicz TE, Ward T</references>
        <references>Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients</references>
        <references>Diseases of the Nervous System</references>
        <references>1960</references>
        <references>21</references>
        <references></references>
        <references>527-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>Not Available</references>
        <references></references>
        <reportingBiasJudgement>N and SD not reported for the Weyburn assessment scale.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Weckowicz-1960</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No information reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>High risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"On the basis of rating they were divided into three matched groups" no further details reported.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1960</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>Drop outs are unaccounted for in the final analysis.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Xiong1994</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries>China</countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double blind.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>12</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </dobj>
        <mainAuthor>Xiong</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>CHLORPROMAZINE versus PLACEBO</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>chlorpromazine</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>12</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control>placebo</Control>
            <group2NameProse></group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>medium term (9 weeks - 6 months)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double blind.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Xiong, Hu</allAuthors>
            <date>1994</date>
            <issue>4</issue>
            <journalName>Medical Journal of Chinese Civil Administration</journalName>
            <originalTitle></originalTitle>
            <pages>160-1</pages>
            <title>A double-blind comparative study of pheytoin and chlorpromazine in chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>6</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Xiong, Hu</allAuthors>
            <date>1994</date>
            <issue>4</issue>
            <journalName>Medical Journal of Chinese Civil Administration</journalName>
            <originalTitle></originalTitle>
            <pages>160-1</pages>
            <title>A double-blind comparative study of pheytoin and chlorpromazine in chronic schizophrenics</title>
            <type>Journal article</type>
            <volume>6</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Xiong, Hu</references>
        <references>A double-blind comparative study of pheytoin and chlorpromazine in chronic schizophrenics</references>
        <references>Medical Journal of Chinese Civil Administration</references>
        <references>1994</references>
        <references>6</references>
        <references>4</references>
        <references>160-1</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>All measured outcomes were reported.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Xiong-1994</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Randomly divided.</selectionBiasRandomSequenceJudgement>
        <setting>HOSPITAL</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1994</year>
    </TRIAL>
</database>
